Implementing Medicaid Health Homes to Provide Medication Assisted Treatment to Opioid Dependent Medicaid Beneficiaries by Smith, Page M.
Kentucky Law Journal
Volume 106 | Issue 1 Article 7
2017
Implementing Medicaid Health Homes to Provide
Medication Assisted Treatment to Opioid
Dependent Medicaid Beneficiaries
Page M. Smith
University of Kentucky College of Law
Follow this and additional works at: https://uknowledge.uky.edu/klj
Part of the Health Law and Policy Commons
Right click to open a feedback form in a new tab to let us know how this document benefits
you.
This Note is brought to you for free and open access by the Law Journals at UKnowledge. It has been accepted for inclusion in Kentucky Law Journal by
an authorized editor of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Smith, Page M. (2017) "Implementing Medicaid Health Homes to Provide Medication Assisted Treatment to Opioid Dependent
Medicaid Beneficiaries," Kentucky Law Journal: Vol. 106 : Iss. 1 , Article 7.
Available at: https://uknowledge.uky.edu/klj/vol106/iss1/7
NO T E S 
 
 
 
111 
 
 
 
Implementing Medicaid Health Homes to Provide 
Medication Assisted Treatment to Opioid Dependent 
Medicaid Beneficiaries 
 
Page M. SmithI 
 
TABLE OF CONTENTS 
 
TABLE OF CONTENTS  .................................................................................................. 111 
INTRODUCTION ............................................................................................................ 112 
I.   EVOLUTION OF THE OPIOID EPIDEMIC  .............................................................. 119 
 A.  Effect of the Exponential Increase in the Rate of Opioid Prescription ..........  119 
 B. The Opioid Crisis Within the Medicaid Population .....................................  121 
II.  ADDRESSING OPIOID MISUSE, OVERDOSE, AND ADDICTION THROUGH 
  MEDICATION ASSISTED TREATMENT ................................................................. 123 
 A.  Proposed Solutions for Addressing Opioid-Related 
  Morbidity and Mortality ................................................................................  123 
 B.  Overview of Medication Assisted Treatment .................................................  125 
 C.  Barriers to the Expansion of Medication Assisted Treatment .......................  127 
 i.  Stigmatization of Opioid Dependence and Medication  
  Assisted Treatment .................................................................................  127 
 ii.  Legal Framework Regulating the Provision of Medication 
  Assisted Treatment .................................................................................  128 
III.  MEDICAID HEALTH HOMES AND THE PROVISION OF MEDICATION  
 ASSISTED TREATMENT ......................................................................................... 131 
 A.  Current State of Medicaid Coverage of Medication Assisted Treatment ......  131 
 B.  Features of a Medicaid Health Home ............................................................  133 
 C. Vermont’s Response to the Opioid Drug Crisis and Features 
  of Vermont’s Medicaid Health Home ...........................................................  134 
 i.  Hubs ........................................................................................................  137 
 ii.  Spokes .....................................................................................................  137 
 D.  The Beneficial Impact of the Hub and Spoke Model ....................................  138 
 E.  Limitations of the Hub and Spoke Model .....................................................  140 
IV. THE EFFICACY OF VERMONT’S MEDICATION ASSISTED  
TREATMENT DELIVERY SYSTEM ................................................................................ 141 
CONCLUSION ................................................................................................................ 143 
                                                                                                                                                                           
I M.P.H. Rollins School of Public Health, Emory University; J.D. Candidate 2018, University of 
Kentucky College of Law. My thanks to Professor Nicole Huberfeld and Dr. Victoria Phillips for their 
encouragement and feedback throughout the writing process. Special thanks to my husband, Corbin 
Smith, for his constant support and boundless patience. 
                                            KENTUCKY LAW JOURNAL                                        Vol. I06 112
INTRODUCTION 
 
In 2011, prescription painkiller overdoses reached epidemic levels,1 with three 
out of every four overdoses attributable to opioid pain relievers.2 In the past fifteen 
years, deaths from prescription opioid overdoses in the United States have 
quadrupled, paralleling a quadruple increase in the rate opioids have been 
prescribed for chronic pain management.3 Unfortunately, when the use of opioids 
expanded in the 1990s, it was not anticipated that the therapeutic benefits of 
opioids would quickly be outweighed by their addictiveness, resulting in not only 
“addiction, overdose, and death,” but also “increasing use and overdoses of heroin 
and illicitly produced fentanyl.”4 Today, opioids have produced the “worst drug 
overdose epidemic in [US] history,”5 creating an ongoing and “urgent need for a 
multifaceted, collaborative public health and law enforcement approach to the 
opioid epidemic . . . . ”6  
The exponential rise in the rate of fatal opioid overdoses largely stemmed from 
the unanticipated consequences of increased use of opioid prescriptions to treat 
chronic pain.7 Beginning in the 1990s, several factors contributed to the significant 
                                                                                                                                                                           
1 Prescription Painkiller Overdoses at Epidemic Levels, CDC (Nov. 1, 2011), 
https://www.cdc.gov/media/releases/2011/p1101_flu_pain_killer_overdose.html [https://perma.cc/QHW3-FLT2]. 
2 NAT’L CTR. FOR INJURY PREVENTION & CONTROL, CDC, Policy Impact: Prescription Painkiller 
Overdoses (Nov. 2011), https://www.cdc.gov/drugoverdose/pdf/policyimpact-prescriptionpainkillerod-a.pdf 
[https://perma.cc/VKY5-FY3G]. Opioids include prescription opioids, fentanyl, and heroin, and are used to reduce 
pain. Opioid Basics, CDC, https://www.cdc.gov/drugoverdose/opioids/index.html [https://perma.cc/XX59-667M] 
(last updated Aug. 24, 2017). Common types of prescription opioids include “oxycodone (Oxycontin), hydrocodone 
(Vicodin), morphine, and methadone.” Id. Fentanyl is a powerful “synthetic opioid pain reliever” used to treat severe 
pain. Id. “Heroin is an illicit opioid synthesized from morphine.” Rose A. Rudd et al., Increases in Drug and Opioid-
Involved Overdose Deaths—United States, 2010–2015, CDC, 65 MORBIDITY & MORTALITY WKLY. REP. 1445, 
1445 n.* (Dec. 30, 2016), https://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm [https://perma.cc/M93C-
U52X]. 
3 Thomas R. Frieden & Debra Houry, Reducing the Risks of Relief — The CDC Opioid-
Prescribing Guideline, 374 NEW ENG. J. MED. 1501, 1501 (2016).  
4 Id.  
5 Andrew Kolodny et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach to 
an Epidemic of Addiction, 36 ANN. REV. PUB. HEALTH 559, 560 (2015) (quoting Leonard J. Paulozzi, 
Medical Epidemiologist, Nat’l Ctr. for Injury Prevention & Control, Grand Rounds Presentation at 
Maimonides Medical Center Department of Psychiatry, Brooklyn, N.Y.: Promising Legal Responses to 
the Epidemic of Prescription Drug Overdoses in the U.S. (Dec. 2, 2010)); see also Frieden & Houry, 
supra note 3, at 1503 (stating that “no other medication routinely used for a nonfatal condition . . . kills 
patients” as frequently as opioids).  
6 Rudd et al., supra note 2, at 1446. 
7 See Prescribing Data, CDC, https://www.cdc.gov/drugoverdose/data/prescribing.html 
[https://perma.cc/QNZ9-LP8R] (last updated Aug. 30, 2017) (reporting that sales of prescription opioids quadrupled 
from 1999–2014, despite no changes in the amount of pain Americans report). Prescription opioids can either be 
immediate-release (IR) or extended release/long acting formulations (ER/LA), but risk of overdose and death is 
significantly higher with “ER/LA formulations.” OFFICE OF THE ASSISTANT SEC’Y FOR PLANNING & 
EVALUATION, U.S. DEP’T OF HEALTH & HUMAN SERVS., OPIOID ABUSE IN THE U.S. AND HHS ACTIONS TO 
ADDRESS OPIOID-DRUG RELATED OVERDOSES AND DEATHS, 2 (Mar. 26, 2015), 
https://aspe.hhs.gov/system/files/pdf/107956/ib_OpioidInitiative.pdf [https://perma.cc/PRN5-CLGW] [hereinafter 
ASPE ISSUE BRIEF ON OPIOID ABUSE 2015] (citing CTR. FOR DRUG EVALUATION & RESEARCH, U.S. FOOD 
& DRUG ADMIN., FINAL RISK EVALUATION AND MITIGATION STRATEGY (REMS) REVIEW 6 (July 22, 2014), 
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rise in opioid prescribing, including: (1) an enhanced physician focus on the 
inadequacy of chronic pain treatment, (2) “new pain management standards from 
the Joint Commission on the Accreditation of Healthcare Organizations,” which 
eventually lead to pain’s recognition as a “fifth vital sign”;8 and, (3) aggressive and 
misleading marketing practices by pharmaceutical companies.9 Unfortunately, 
widespread opioid prescriptions preceded the development of  
research-based prescribing guidelines that accounted for the efficacy, “safety, and 
economic efficiency of long-term opioid therapy.”10 Although some professional 
organizations, states, and federal agencies have devised clinical guidelines for opioid 
prescribing, the Centers for Disease Control and Prevention (CDC) published the 
first evidence-based, uniform prescribing guidelines in March 2016.11 Ultimately, 
the lack of consensus on appropriate prescribing resulted in over-prescription and 
erratic prescription rates across states that cannot be explained by underlying 
variations in a state’s health status.12  
Thus, as opioid overdose deaths continue to rise across the U.S.,13 prevention, 
treatment, and development of an effective response to opioid abuse have become 
pressing public health initiatives for state and federal governments.14 In 2015, the 
                                                                                                                                                                           
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf [https://perma.cc/QZ2H-
Z7BB]).  
8 Kathryn F. Hawk et al., Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm 
Reduction Strategies, 88 YALE J. BIOLOGY & MED. 235, 236 (2015) (citations omitted), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553643/pdf/yjbm_88_3_235.pdf 
[https://perma.cc/8Z2F-G5K4]; see also Gary Franklin et al., A Comprehensive Approach to Address 
the Prescription Opioid Epidemic in Washington State: Milestones and Lessons Learned, 105 AM. J. 
PUB. HEALTH, 463, 464 (2015) (discussing “[t]he development of pain as the ‘fifth vital sign.’” But see 
David W. Baker, Joint Commission Statement on Pain Management, JOINT COMMISSION (Apr. 18, 
2016) (denying that the 2001 Joint Commission standards formally recognized pain as a vital sign).  
9 Frieden & Houry, supra note 3, at 1501; Hawk et al., supra note 8, at 236.  
10 Frieden & Houry, supra note 3, at 1501; Hawk et al., supra note 8, at 236.  
11 Deborah Dowell et al., CDC Guideline for Prescribing Opioids for Chronic Pain — United 
States, 2016, CDC, 65 MORBIDITY & MORTALITY WKLY. REP. 1, 1–3 (Mar. 18, 2016), 
https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm [https://perma.cc/L9XE-8EGH]. The 
CDC’s guidelines were based on an intensive systematic review of scientific evidence and the input of 
experts and practitioners, federal agencies, professional and advocacy organizations, patient and provider 
groups, a federal advisory committee, peer reviewers, and public comments. Id. at 4–8; Frieden & 
Houry, supra note 3, at 1503.  
12 Dowell et al., supra note 11, at 1 (citing Leonard J. Paulozzi et al., Vital Signs: Variation Among States in 
Prescribing of Opioid Pain Relievers and Benzodiazepines – United States, 2012, CDC, 63 MORBIDITY & 
MORTALITY WKLY. REP. 563 (July 4, 2014), https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6326a2.htm 
[https://perma.cc/6E7A-TSUX]). 
13 Rudd et al., supra note 2, at 1445. From 2014 to 2015 alone, drug overdoses involving an opioid 
increased approximately 15%. Id. at 1446 (calculating the percent change between 33,091 deaths 
involving an opioid in 2015 and 28,647 involving an opioid in 2014). But, the “rapid increase in deaths 
appears to be driven by heroin and synthetic opioids other than methadone” rather than prescription 
opioids (natural/semisynthetic opioids). Id. 
14 U.S. DEP’T OF HEALTH & HUMAN SERVS., THE OPIOID EPIDEMIC: BY THE NUMBERS 1, 
https://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf [https://perma.cc/TSY2-XY66] 
                                            KENTUCKY LAW JOURNAL                                        Vol. I06 114  
U.S. Department of Health and Human Services (HHS) announced its 
commitment to decrease opioid overdoses, the prevalence of opioid use disorder,15 
and overall overdose mortality.16 To achieve these goals, the Secretary’s initiative 
focused on (1) opioid prescribing practices, (2) use and distribution of naloxone,17 
and (3) access to Medication Assisted Treatment (MAT),18 areas targeting several 
of the interconnected dimensions of the opioid epidemic. This Note will examine 
access to MAT, analyzing the efficacy of an innovative care model that several 
states have implemented in their Medicaid programs to deliver MAT to opioid 
dependent beneficiaries.  
Prior to enactment of the Patient Protection and Affordable Care Act (ACA),19 
Medicaid’s role in financing substance abuse treatment was limited.20 But, three 
provisions of the ACA, in combination with the Mental Health Parity and 
Addiction Equity Act of 2008 (“Equity Act”),21 are expected to transform 
Medicaid into the largest payer of addiction treatment.22 First, by offering states 
                                                                                                                                                                           
(last updated June 2016) [hereinafter HHS OPIOID EPIDEMIC: BY THE NUMBERS]; see also ASPE 
ISSUE BRIEF ON OPIOID ABUSE 2015, supra note 7, at 1 (“addressing the opioid abuse problem” is a 
“high priority” for HHS).  
15 Opioid use disorder is also referred to as “opioid abuse or dependence” or “opioid addiction.” 
Opioid Basics, supra note 2. This Note will use those terms interchangeably.  
16 ASPE ISSUE BRIEF ON OPIOID ABUSE 2015, supra note 7, at 1. 
17 Naloxone is a drug that reverses both prescription opioid and heroin overdoses. ASPE ISSUE 
BRIEF ON OPIOID ABUSE Id. at 5.  
18 Id. at 1. Medication Assisted Treatment (MAT) involves the use of three FDA-approved 
medications for treating opioid use disorders, including methadone, buprenorphine, or naltrexone, “in 
combination with counseling and behavioral therapies, to provide a  
whole-patient approach to the treatment of substance use disorders, including opioid use disorders.” ASPE 
ISSUE BRIEF ON OPIOID ABUSE 2015, supra note 7, at 6; see also CMCS Informational Bulletin from 
Dirs. and Adm’rs of Various Pub. Health-Related Fed. Agencies on Medication Assisted Treatment for 
Substance Use Disorders 1, 3–4 (July 11, 2014), https://www.medicaid.gov/Federal-Policy-
Guidance/Downloads/CIB-07-11-2014.pdf [https://perma.cc/64HC-JXSD]. 
19 Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010) 
(codified in scattered sections of 42 U.S.C.). 
20 Christina Andrews et al., Lessons from Medicaid’s Divergent Paths on Mental Health and 
Addiction Services, 34 HEALTH AFF. 1131, 1132–33 (2015); see also Jeffrey A. Buck, The Looming 
Expansion and Transformation of Public Substance Abuse Treatment Under the Affordable Care Act, 
30 HEALTH AFF. 1402, 1402–03, 1408 (2011) (discussing the ACA’s potential to integrate substance 
abuse treatment system into “mainstream of general health care”). Andrews et al. use addiction 
treatment synonymously with substance abuse treatment. See Andrews et al, supra.  
21 Emergency Economic Stabilization Act of 2008, Pub. L. No. 110–343, § 512, 112 Stat. 3765, 
3881–93.  
22 Andrews et al., supra note 20, at 1131–33; see also KIRSTEN BERONIO ET AL., U.S. DEP’T OF HEALTH 
& HUMAN SERVS., AFFORDABLE CARE ACT WILL EXPAND MENTAL HEALTH AND SUBSTANCE USE 
DISORDER BENEFITS AND PARITY PROTECTIONS FOR 62 MILLION AMERICANS, 1, 3–4 (Feb. 2013), 
https://aspe.hhs.gov/system/files/pdf/76591/rb_mental.pdf [https://perma.cc/WWK3-ZZDX] (estimating that 
62.5 million Americans (both Medicaid and non-Medicaid beneficiaries) will gain access to mental health and 
substance abuse benefits through the ACA and federal parity protections). But see Christina Andrews et al., 
Despite Resources from the ACA, Most States Do Little to Help Addiction Treatment Programs Implement 
Health Care Reform, 34 HEALTH AFF. 828, 834 (2015) (stating the ACA “has great potential to improve access 
to addiction treatment,” but that the “implementation poses great challenges to the addiction treatment system”); 
Michael C. Barnes & Stacey L. Worthy, Achieving Real Parity: Increasing Access to Treatment for Substance 
Use Disorders Under the Patient Protection and Affordable Care Act and the Mental Health and Addiction 
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the ability to expand Medicaid to those under age 65 earning up to 133% of the 
Federal Poverty Level (FPL),23 the ACA allows expansion states to greatly increase 
the number of beneficiaries eligible to receive substance abuse benefits.24 Second, 
the ACA designates mental health and substance use disorder services as Essential 
Health Benefits (EHBs),25 signifying that all insurance plans in the individual and 
small group markets, 26 as well as Medicaid Alternative Benefit Plans,27 must cover 
such services.28 Finally, the ACA makes the requirements of the Equity Act 
applicable to individual, small group,29 and Alternative Benefit Plans,30 thereby 
preventing the imposition of “financial requirements and treatment limitations” on 
substance abuse and mental health services that are “more restrictive than those 
                                                                                                                                                                           
Equity Act, 36 U. ARK. LITTLE ROCK L. REV. 555, 557 (2014) (arguing that “prejudices” and 
“misunderstandings” about substance use disorders continue to thwart increased access to treatment despite passage 
of the ACA and the Mental Health Parity and Addiction Equity Act of 2008). At time of publication of this 
Note, Congress’s “repeal-and-replace effort[s]” have failed three times in 2017, Rachel Roubein, Timeline: The 
GOP’s Failed Effort to Repeal ObamaCare, HILL (Sept. 26, 2017, 8:02 PM), 
http://thehill.com/policy/healthcare/other/352587-timeline-the-gop-effort-to-repeal-and-replace-obamacare 
[https://perma.cc/ZGW4-SRA9], “demonstrat[ing] the difficulty in amending, let alone repealing, an imperfect 
law that over seven years has extended health insurance coverage to many Americans.” KATHRYN S. BEARD & 
PAUL T. CLARK, DELAY, DEREGULATE, DERAIL – HEALTH CARE ROILED BY ACTIONS OF TRUMP AND 
CONGRESS 13 WOLTERS KLUWER (July 14, 2017). While the ACA’s future remains uncertain, it is clear “federal 
spending on Medicaid and the opioid epidemic” will remain key points of contention in any future proposed 
health care bills. See Robert Pear & Jennifer Steinhauer, G.O.P. Rift over Medicaid and Opioids Imperils Senate 
Health Bill, N.Y. TIMES (June 20, 2017), https://www.nytimes.com/2017/06/20/us/politics/health-care-
medicaid-opioid.html [https://perma.cc/KQ7L-3RWP].  
23 See Patient Protection and Affordable Care Act, Pub. L. No. 111–148, § 2001(a)(5), 124 Stat. 
119, 274 (2010) (codified as amended at 42 U.S.C. § 1396a(l)(2)(C) (2012)). Under NFIB v. Sebelius, 
132 S. Ct. 2566, 2607–08 (2012), states were given the option to expand Medicaid.  
24 See Andrews et al., supra note 22, at 828 (estimating that if all states expanded Medicaid, 
approximately five million uninsured Americans suffering from substance abuse could be eligible to 
receive insurance through Medicaid or insurance exchanges).  
25 See 42 U.S.C. § 18022 (2012 & Supp. III 2012). EHBs include the following categories of 
services: (1) ambulatory patient services, (2) emergency services, (3) hospitalization, (4) maternity and 
newborn care, (5) mental health and substance use disorder services, including behavioral health 
treatment, (6) prescription drugs, (7) rehabilitative and habilitative services and devices, (8) laboratory 
services, (9) preventive and wellness services and chronic disease management, and (10) pediatric 
services. Id. § 18022(b)(1) (2012). Within each of these categories, the Secretary of HHS is responsible 
for ensuring that the scope of benefits offered is “equal to the scope of benefits provided under a typical 
employer plan” and adequately accounts for the health care needs of a diverse patient population. Id. § 
18022(b)(2)(A), (b)(4).  
26 45 C.F.R. § 147.150(a) (2017).  
27 Alternative Benefit Plans cover most adults in the expansion population and are equivalent to 
what was previously described as benchmark coverage, or a plan satisfying the minimum Medicaid 
requirements. 42 U.S.C. § 1396u-7(a)(1)(A), (b) (2012); Julia Paradise, Medicaid Moving Forward, 
KAISER FAMILY FOUND. 4–5 (Mar. 9, 2015), http://kff.org/health-reform/issue-brief/medicaid-
moving-forward/ [https://perma.cc/HX2Z-P48E].  
28 42 C.F.R. § 440.335(b) (2017).  
29 45 C.F.R. §§ 146.136, 147.160(a) (2017). 
30 42 U.S.C. § 1396u-7(b)(6). 
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placed on medical and surgical benefits.”31 Consequently, as states attempt to 
address the rampant opioid epidemic, their Medicaid programs will play an 
important function, especially in funding prevention and treatment.32  
In addition to Medicaid’s enhanced financing role, Medicaid beneficiaries are 
disproportionately affected by the opioid epidemic.33 Individuals with opioid 
dependency constitute a small portion of the total Medicaid population,34 but in 
comparison to the general population, Medicaid recipients are more likely to be 
prescribed opioids,35 die from opioid overdoses,36 experience heroin abuse or 
dependence,37 and suffer from comorbid conditions that diminish the efficacy of 
treatment.38 Furthermore, because states dedicate a large percentage of their 
budgets to fund Medicaid,39 and a minority of enrollees generate the majority of 
                                                                                                                                                                           
31 Buck, supra note 20, at 1403. The Equity Act applies to group health plans, including Medicaid 
managed care. Id. But, the Equity Act is limited in its application because it does not mandate coverage 
of mental health and substance abuse. Barnes & Worthy, supra note 22, at 567. Rather, it only requires 
equivalent coverage for plans choosing to cover mental health and substance abuse. Id. (citing 29 U.S.C. 
§ 1185a(b) (2012)). 
32 See Deborah Bachrach et al., Medicaid: States’ Most Powerful Tool to Combat the Opioid 
Crisis, STATE HEALTH REFORM ASSISTANCE NETWORK 4 (July 2016), http://statenetwork.org/wp-
content/uploads/2016/07/State-Network-Manatt-Medicaid-States-Most-Powerful-Tool-to-Combat-
the-Opioid-Crisis-July-2016.pdf [https://perma.cc/B8M9-LSSB] (“Medicaid is the most powerful 
vehicle available to states to fund coverage of prevention and treatment for residents at risk for or 
actively battling opioid addiction.”).  
33 CMCS Informational Bulletin from Vikki Wachino, Dir., Ctr. for Medicaid & CHIP Servs., on 
Best Practices for Addressing Prescription Opioid Overdoses, Misuse, & Addiction 2  
(Jan. 28, 2016), https://www.medicaid.gov/federal-policy-guidance/downloads/CIB-02-02-16.pdf 
[https://perma.cc/785T-NJJU] [hereinafter CMS Best Practices for Addressing Prescription Opioid 
Overdoses, Misuse, & Addiction]. 
34 Kathy Moses & Julie Klebonis, Designing Medicaid Health Homes for Individuals with Opioid 
Dependency: Considerations for States, CTRS. FOR MEDICARE & MEDICAID SERVS. 1 (Jan. 2015), 
https://www.medicaid.gov/state-resource-center/medicaid-state-technical-assistance/health-homes-
technical-assistance/downloads/health-homes-for-opiod-dependency.pdf [https://perma.cc/5389-
VZYG]. 
35 CMS Best Practices for Addressing Prescription Opioid Overdoses, Misuse, & Addiction, supra 
note 33, at 2.  
36 Tami L. Mark et al., Medicaid Coverage of Medications to Treat Alcohol and Opioid 
Dependence, 55 J. SUBSTANCE ABUSE TREATMENT 1, 1 (2015), (citing Bridget M. Kuehn, Payers 
Probe Ways to Help Curb Risky Prescribing, 311 JAMA 1097, 1098 (2014)). 
37 New Research Reveals the Trends and Risk Factors Behind America’s Growing Heroin 
Epidemic, CDC, (July 7, 2015, 1:00 PM), https://www.cdc.gov/media/releases/2015/p0707-heroin-
epidemic.html [https://perma.cc/75B2-7GM7].  
38 Robin E. Clark et al., Risk Factors for Relapse and Higher Costs Among Medicaid Members 
with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History, 57 J. 
SUBSTANCE ABUSE TREATMENT 75, 75, 77 (2015); see also U.S. GOV’T ACCOUNTABILITY OFFICE, 
GAO-15-449, BEHAVIORAL HEALTH: OPTIONS FOR LOW-INCOME ADULTS TO RECEIVE 
TREATMENT IN SELECTED STATES 1–2, 6–7 (June 2015), http://www.gao.gov/assets/680/670894.pdf 
[https://perma.cc/GL6V-HV9D] [hereinafter GAO: BEHAVIORAL HEALTH] (highlighting the 
increased prevalence of behavioral conditions among Medicaid patients and the benefits of appropriate 
treatment). 
39 See Robin Rudowitz, Medicaid Financing: The Basics, KAISER FAMILY FOUND. 8–9 (Dec. 22, 
2016), http://kff.org/medicaid/issue-brief/medicaid-financing-the-basics/ [https://perma.cc/NE2L-
ZN4S]. 
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spending,40 states are constantly seeking cost-effective solutions to manage the 
complex health care needs of their Medicaid populations.41  
A provision in the ACA encourages states to establish health homes, which 
combine physical and behavioral health42 and long-term services, to provide higher 
quality and more individualized care to Medicaid beneficiaries with chronic 
conditions.43 As of May 2017, twenty-one states and the District of Columbia are 
operating Medicaid health homes, but only three of those states, Maryland, Rhode 
Island, and Vermont, have designed health homes specifically to target those with 
opioid dependency.44 
Although Medicaid expansion may have the most dramatic impact on a state’s 
capacity to provide treatment for opioid dependency,45 this Note will consider how 
                                                                                                                                                                           
40 See id. at 4–5 (stating that elderly and disabled persons make up one-quarter of Medicaid 
enrollees, but account for almost two-thirds of Medicaid spending); KAISER COMM’N ON MEDICAID 
& THE UNINSURED, Medicaid Health Homes for Beneficiaries with Chronic Conditions, KAISER 
FAMILY FOUND. 4 (Aug. 2012), https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8340.pdf 
[https://perma.cc/9CBR-BMAQ] [hereinafter KAISER, Medicaid Health Homes] (“[O]ver half of all 
Medicaid spending is attributable to the 5% of Medicaid beneficiaries with the highest costs.”).  
41See KAISER, Medicaid Health Homes, supra note 40, at 4 (noting that almost half of disabled 
Medicaid beneficiaries suffer from mental illness and nearly half have three or more chronic conditions). 
Major chronic conditions are prevalent among all Medicaid beneficiaries, with “more than 1 in 10” 
diagnosed with diabetes. Id.  
42 Services treating mental health and substance abuse conditions are considered behavioral health 
treatments. See GAO: BEHAVIORAL HEALTH, supra note 38, at 6–7. 
43 See 42 U.S.C. § 1396w-4 (2012); CTRS. FOR MEDICARE & MEDICAID SERVS., Medicaid Health 
Homes: An Overview 1 (May 2015), https://www.medicaid.gov/state-resource-center/medicaid-state-technical-
assistance/health-homes-technical-assistance/downloads/medicaid-health-homes-overview.pdf 
[https://perma.cc/TS9G-5P3L] [hereinafter CMS, Health Home Overview]; Health Homes, MEDICAID.GOV, 
https://www.medicaid.gov/medicaid/ltss/health-homes/index.html [https://perma.cc/67V7-AQ8R] (last visited 
Nov. 2, 2017). Under § 1396w-4(h)(B)(2), substance use disorder is considered a chronic condition. 
44 See CTRS. FOR MEDICARE & MEDICAID SERVS., Medicaid Health Homes: SPA Overview (May 
2017), https://www.medicaid.gov/state-resource-center/medicaid-state-technical-assistance/health-homes-
technical-assistance/downloads/hh-spa-overview.pdf [https://perma.cc/A6XK-93LP] [hereinafter CMS, 
Medicaid Health Homes: SPA Overview]; see also CTRS. FOR MEDICARE & MEDICAID SERVS., Approved 
Medicaid Health Home State Plan Amendments, https://www.medicaid.gov/state-resource-center/medicaid-
state-technical-assistance/health-homes-technical-assistance/downloads/hh-map.pdf [https://perma.cc/Y6EV-
2YSJ] (last updated May 2017). Each state implemented its Medicaid health home in 2013, Moses & Klebonis, 
supra note 34, at 3, but since that time Maryland appears to have broadened the focus of its health home from 
opioid use disorder to substance abuse disorder generally. Compare CTRS. FOR MEDICARE & MEDICAID 
SERVS., State-by-State Health Home State Plan Amendment Matrix 3, https://www.medicaid.gov/state-
resource-center/medicaid-state-technical-assistance/health-homes-technical-assistance/downloads/hh-spa-at-a-
glance-jul-2016.pdf [https://perma.cc/WJC6-YZ2V] (last updated July 2016) (showing that Maryland’s target 
health home population included persons with opioid substance use disorder), with CMS, Medicaid Health 
Homes: SPA Overview, supra, at 2 (providing that Maryland’s home health model focuses on substance use 
disorder treatment generally).  
45 See generally JUDITH DEY ET AL., BENEFITS OF MEDICAID EXPANSION FOR BEHAVIORAL 
HEALTH, U.S. DEP’T OF HEALTH & HUMAN SERVICES (Mar. 28, 2016), 
https://aspe.hhs.gov/sites/default/files/pdf/190506/BHMedicaidExpansion.pdf [https://perma.cc/BTP3-
LSXN] (discussing expansion states’ enhanced ability to care for beneficiaries with mental illness or 
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the health home model, regardless of a state’s expansion status and present 
uncertainty surrounding the ACA’s future,46 offers all states an innovative approach 
to restructuring their Medicaid programs to better serve the complex needs of 
opioid dependent beneficiaries.47 Specifically, this Note will examine the features of 
Vermont’s Medicaid health home, assessing the benefits and challenges of 
Vermont’s system and the feasibility of implementing the model in other states to 
deliver MAT to Medicaid recipients. Facing rising rates of prescription opioid 
abuse and dependence and heroin use, increasing health care expenditures on 
opioid dependent beneficiaries, and a failing treatment system, Vermont adopted 
its Hub and Spoke health home model to improve access to and the quality of 
MAT for its Medicaid beneficiaries.48 But, unlike Maryland and Rhode Island,49 in 
organizing its health home, Vermont integrated the two existing, but historically 
distinct providers of MAT, opioid treatment programs and buprenorphine 
prescribing physicians, to enhance care coordination, treatment capacity, and the 
provision of individualized care.50  
Part I will explore the evolution of opioid epidemic and the adverse health 
outcomes that have resulted from increased opioid consumption, especially among 
Medicaid beneficiaries. Part II will discuss the solutions that are being proposed to 
curb opioid misuse, overdose, and addiction, focusing particularly on the provision 
of MAT and the issues plaguing access to substance abuse treatment in the U.S. 
Part III will examine the implementation and characteristics of Medicaid health 
                                                                                                                                                                           
substance use disorder); see also Deborah Bachrach et al., supra note 32, at 1 (stating that “Medicaid is a far 
more powerful weapon” against the opioid epidemic in states that expanded Medicaid).  
46 See Peter D. Friedmann et al., How ACA Repeal Would Worsen the Opioid Epidemic, 376 NEW ENG. J. 
MED. e16(1), e16(2) (2017), http://www.nejm.org/doi/pdf/10.1056/NEJMp1700834 [https://perma.cc/JPD9-
XUDD] (noting that with Donald Trump’s profession to repeal the ACA, the “future of the ACA is precarious at 
best”). But see supra note 22 (evidencing that repeal and replace efforts have failed three times since the time 
Friedmann et al. was published). Nonetheless, President Trump has “vowed . . . that Republican efforts to repeal and 
replace the Affordable Care Act are not finished,” Phil Mattingly, Trump Vows GOP Will Continue Efforts to 
Repeal Obamacare, CNN (Sept. 27, 2017, 2:56 PM), http://www.cnn.com/2017/09/27/politics/donald-trump-
health-care-republicans/index.html [https://perma.cc/EA3N-GLJR], evidenced by his October 12, 2017, executive 
order eliminating “subsidies to health insurance companies that help pay out-of-pocket costs of low-income people . . . 
.” Robert Pear et al., Trump to Scrap Critical Health Care Subsidies, Hitting Obamacare Again, N.Y. TIMES (Oct. 
12, 2017) https://www.nytimes.com/2017/10/12/us/politics/trump-obamacare-executive-order-health-insurance.html 
[https://perma.cc/PXA5-VCXA]. 
47 See Buck, supra note 20, at 1404 (noting that ACA provisions other than Medicaid expansion 
have the opportunity to “affect the financing and character of public substance abuse treatment 
services”).  
48 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DE BEAUMONT FOUND., 
VERMONT CASE STUDY: MEDICATION ASSISTED TREATMENT PROGRAM FOR OPIOID 
ADDICTION 10, 13 (May 2014), http://www.astho.org/Health-Systems-Transformation/Medicaid-
and-Public-Health-Partnerships/Case-Studies/Vermont-MAT-Program-for-Opioid-Addiction/ 
[https://perma.cc/C8F8-45WY].  
49 See Moses & Klebonis, supra note 34 (comparing the features of each state’s medical home).  
50 Karen L. Casper & Anthony Folland, Essential Elements of Vermont’s “Hub and Spoke” Health 
Homes Model, in MODELS OF INTEGRATED PATIENT CARE THROUGH OTPS AND DATA 2000 
PRACTICES (Am. Ass’n for the Treatment of Opioid Dependence) 6–7, 10–11 (Feb. 22, 2016), 
http://www.aatod.org/policies/mat-hub-setting-whitepapers/ [https://perma.cc/JXF7-LEXU] (follow 
“Whitepaper #1” hyperlink). 
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homes, concentrating on the features of Vermont’s system, including the impact it 
has had on MAT delivery and its ability to address the traditional shortcomings in 
the delivery of MAT. Finally, Part IV will consider the efficacy of Vermont’s 
system, its limitations and its generalizability to other states seeking solutions to 
address opioid morbidity and mortality.  
 
I.  EVOLUTION OF THE OPIOID EPIDEMIC 
 
A.  Effect of the Exponential Increase in the Rate of Opioid Prescription 
 
Despite debates surrounding the effect increased consumption and prescription 
of opioids has had on the prevalence of nonmedical opioid use,51 or use of opioids 
without a prescription or in a manner other than as prescribed,52 evidence shows 
the morbidity and mortality associated with nonmedical use is intensifying.53 Over 
the last decade, emergency department visits and drug overdose deaths involving 
prescription opioids have increased exponentially;54 and, the prevalence of opioid 
use disorder, or “problematic pattern[s] of opioid use leading to clinically 
significant impairment,”55 among nonmedical users has risen nearly 125%.56 
                                                                                                                                                                           
51 Compare Beth Han et al., Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 
Through 64 Years in the United States, 2003–2013, 314 JAMA 1468, 1471–72 (2015), 
http://jamanetwork.com/journals/jama/fullarticle/2456166 [https://perma.cc/HEF3-K4XX] (follow “Download 
PDF” hyperlink) (finding that “the percentage of nonmedical use of prescription opioids decreased” from 2003–2013), 
and Christopher M. Jones, The Paradox of Decreasing Nonmedical Opioid Analgesic Use and Increasing Abuse or 
Dependence – An Assessment of Demographic and Substance Use Trends, United States, 2003–2014, 65 
ADDICTIVE BEHAVIORS 229, 231, 233 (2016) (finding a decline in nonmedical opioid use between 2003–2005 and 
2012–2014), with Tulshi D. Saha et al., Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription 
Opioid Use Disorder in the United States, 77 J. CLINICAL PSYCHIATRY 772, 776 (2016), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555044/pdf/nihms882236.pdf [https://perma.cc/YH22-M9XB] 
(finding that the prevalence of 12-month and lifetime nonmedical opioid use increased from 1.8% and 4.7%, 
respectively, in 2001–2002 to 4.1% and 11.3% in 2012–2013). 
52 Kolodny et al., supra note 5, at 563. Nonmedical opioid use is also considered use of opioids for 
the experience or feeling they cause, id. at 563, or use of illicit opioids. Hawk et al., supra note 8, at 236.  
53 See Han et al., supra note 51, at 1472–74, 1477 (noting that despite the decrease in the 
percentage of nonmedical use, the “morbidity and mortality associated with nonmedical use of 
prescription opioids” has increased); Jones, supra note 51, at 231–33 (noting that the “encouraging” 
decreasing trends in nonmedical use are “tempered by the significant increases in rates of . . . opioid . . . 
abuse or dependence”); Saha et al., supra note 51, at 776 (finding that the increased prevalence of 
nonmedical opioid use produced a corresponding increase in “[nonmedical prescription opioid use]-
associated morbidity and mortality.” 
54 Han et al., supra note 51, at 1469.  
55 AGENCY FOR HEALTHCARE RESEARCH & QUALITY, U.S. DEP’T OF HEALTH & HUMAN 
SERVICES, Medication-Assisted Treatment Models of Care for Opioid Use Disorder 1 (Feb. 24, 2016), 
https://ahrq-ehc-application.s3.amazonaws.com/media/pdf/opioid-use-disorder_research-protocol.pdf 
[https://perma.cc/7YR9-44WN] (quoting Opioid Use Disorder Diagnostic Criteria, Substance-Related 
and Addictive Disorders, in AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF 
MENTAL DISORDERS 1 (5th ed. 2013), http://pcssmat.org/wp-content/uploads/2014/02/5B-DSM-5-
Opioid-Use-Disorder-Diagnostic-Criteria.pdf [https://perma.cc/MHE5-NDDK]). Opioid use 
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Statistics may show that rates of nonmedical use have remained relatively stable, 
but the frequency and intensity of prescription opioid use among nonmedical users 
has increased significantly, resulting in a corresponding rise in the rates of opioid 
abuse or dependence.57 In addition to problems with opioid dependence, the 
misuse of prescription opioids is also closely connected to the rise in the use of 
illicit opioids, including heroin and illicitly manufactured fentanyl.58 The addictive 
nature of prescription opioids makes nonmedical use “a significant risk factor for 
heroin use,”59 with “four in five new heroin users start[ing] out by misusing 
prescription opioids.”60 Moreover, while the majority of nonmedical users obtain 
medications from a friend or relative, frequent nonmedical users, those with the 
highest use and therefore the highest risk of overdose, most often obtain opioids 
from physician prescriptions.61  
But, regardless of whether a person uses opioids medically as prescribed or 
nonmedically,62 merely initiating treatment with opioids enhances the risk of opioid 
use disorder, overdose, and addiction.63 A recent study found that 1 in 550 patients 
“receiving opioids for chronic noncancer pain . . . died from opioid-related overdose 
                                                                                                                                                                           
disorder also “involves misuse or abuse of prescription opioids or illicit heroin.” Id. Characteristics of 
opioid use disorder include: “unsuccessful efforts to cut down or control use” and use resulting in social 
problems and “a failure to fulfill major role obligations at work, school, or home.” Opioid Use Disorder 
Diagnostic Criteria, supra, at 1.  
56 Saha et al., supra note 51, at 772–73, 776.  
57 Han et al., supra note 51, at 1472; Jones, supra note 51, at 230, 233. 
58 Rudd et al., supra note 2, at 1450; Frieden & Houry, supra note 3, at 1501.  
59 Rudd et al., supra note 2, at 1450.  
60 HHS OPIOID EPIDEMIC: BY THE NUMBERS, supra note 14, at 2; see Opioids, SUBSTANCE 
ABUSE & MENTAL HEALTH SERVS. ADMIN., https://www.samhsa.gov/atod/opioids 
[https://perma.cc/8G22-YJW8] (last updated Feb. 23, 2016) (describing how repeated use of opioids 
increases one’s tolerance, which may ultimately lead a person to turn to the black market for prescription 
drugs and illicit opioids).  
61 Christopher M. Jones et al., Research, Letter, Sources of Prescription Opioid Pain Relievers by 
Frequency of Past-Year Nonmedical Use: United States, 2008–2011, 174 JAMA INTERNAL MED. 802, 
802–03 (2014), http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1840031 (follow 
“Download PDF” hyperlink) [https://perma.cc/C8QP-MJH4]. The majority of nonmedical users 
reported 1 to 199 days of nonmedical use, while the highest risk group reported 200 to 365 days of 
nonmedical use. Id. Those in the highest risk group were also more likely to receive drugs from drug 
dealers. Id.  
62 Medical opioid users are those taking opioid pain relievers as prescribed. Hawk et al., supra note 
8, at 236. But, “[t]he pathophysiology and acute medical management of an opioid overdose [are] 
similar irrespective of whether the opioid that was taken was legally prescribed or illegally bought . . . .” 
Id. at 237. Even “strict adherence to instructions” does not protect a person from “fatal overdose.” Id. at 
236.  
63 Dowell et al., supra note 11, at 2; Frieden & Houry, supra note 3, at 1501. Opioid use disorder is 
often referred to as “abuse or dependence” and “is different from tolerance (diminished response to a 
drug with repeated use) and physical dependence (adaptation to a drug that produces symptoms of 
withdrawal when the drug is stopped).” Dowell et al., supra note 11, at 2. Overdose is “[i]njury to the 
body” that occurs “when a drug is taken in excessive amounts.” Opioid Basics, supra note 2. The injury 
caused by an overdose can be fatal or nonfatal. Id. Addiction is “continued use of a drug despite negative 
consequences.” Kolodny et al., supra note 5, at 560. 
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at a median of 2.6 years” from the date of first prescription,64 demonstrating that a 
history of being prescribed opioid pain medications increases the likelihood of 
adverse health outcomes.65 Consequently, repeated exposure to opioids places both 
individuals using opioids for pain relief and nonmedical users at higher risk of 
developing addiction.66  
Ultimately, the exponential increase in the prescription and use of opioids 
underlies both “distinct but interconnected trends” defining the current opioid 
epidemic: (1) a 15-year increase in prescription opioid overdose deaths and (2) a 
rise in illicit opioid overdoses. 67 
 
B.  The Opioid Crisis Within the Medicaid Population  
 
Although opioid prescribing has increased dramatically among both privately 
and publicly insured populations,68 the detrimental effects of overprescribing are 
particularly concerning for the Medicaid population. At the outset, one’s status as a 
Medicaid beneficiary increases the odds of suffering from opioid abuse or 
dependence.69 The Medicaid population disproportionately suffers from the 
following risk factors, shown to make one more susceptible to prescription opioid 
abuse: (1) “overlapping prescriptions from multiple providers and pharmacies;”70 (2) 
                                                                                                                                                                           
64 Dowell et al., supra note 11, at 2 (citing Eric Kaplovitch et al., Sex Differences in Dose 
Escalation and Overdose Death During Chronic Opioid Therapy: A Population-Based Cohort Study, 
PLOSONE, Aug. 20, 2015, at 1, 4–7). The rate of death was even more dramatic as opioid dosages 
increased, escalating to one in thirty-two for patients receiving more than 200 morphine milligram 
equivalents. Id. 
65 Id. 
66 Kolodny et al., supra note 5, at 560. 
67 Opioid Data Analysis, CDC, https://www.cdc.gov/drugoverdose/data/analysis.html 
[https://perma.cc/TU6U-QJKX] (last updated Feb. 9, 2017); see also Frieden & Houry, supra note 3, at 
1501 (noting that the quadrupled rate of opioid prescribing in the past fifteen years is “tightly 
correlated” with the quadruple increase in deaths from prescription opioid overdose). From 1999–2015, 
the majority of drug overdoses involved an opioid, but the increase in the “opioid-involved death rate” 
from 2014–2015 seems to be attributable to heroin and illicitly manufactured fentanyl. Rudd et al., 
supra note 2, at 1445–46.  
68 Mark D. Sullivan et al., Trends in Use of Opioids for Non-Cancer Pain Conditions 2000–2005 
in Commercial and Medicaid Insurance Plans: The TROUP Study, 138 PAIN 440, 447–48 (2008).  
69 See Han et al., supra note 51, at 1470 (finding that the prevalence of opioid use disorders was 
higher among Medicaid beneficiaries); Jones, supra note 51, at 233.  
70 Prescription Opioids: Risk Factors, CDC (footnotes omitted), 
https://www.cdc.gov/drugoverdose/opioids/prescribed.html [https://perma.cc/T3B8-43KB] (follow 
“Risk Factors” tab) (last updated Aug. 29, 2017); see Zhuo Yang et al., Defining Risk of Prescription 
Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions Among Long-Term Opioid 
Users in Medicaid, 16 J. PAIN 445, 449–50 (2015) (finding that among a population of 90,010 
Medicaid beneficiaries using opioids long-term, 6.7% had both “pharmacy shopping behavior and 
overlapping prescriptions,” making this population six times more likely to overdose than those with 
neither condition). Beneficiaries with overlapping prescriptions only were more likely to overdose than 
those with pharmacy shopping only. Id. at 450. Because there is no uniform definition of “pharmacy 
shopping,” the study examined several combinations of time intervals (90 days, 180 days, and 1 year) 
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“high daily doses of prescription pain relievers;”71 (3) “mental illness or a history of 
alcohol or other substance abuse;”72 and, (4) “living in rural areas and having low 
income.”73 A study examining the prevalence of indicators of misuse and 
inappropriate opioid prescribing among Medicaid beneficiaries found that 
Medicaid patients were more likely than privately insured patients to be suffering 
from at least one or more adverse indicators at the time of their prescription.74 In 
                                                                                                                                                                           
and the number of pharmacies visited during the time interval (≥3, ≥4, ≥5). Id. at 447. Yang et al. found 
that regardless of time interval, the percentage of patients with overdose events increased linearly as the 
number of pharmacies used increased. Id. at 448. “Overlapping prescriptions were defined as [two] 
prescriptions of the same drug type that overlapped by ≥25% of the days prescribed, with the initial 
dispensed prescription having a supply time of five days or longer.” Id. at 447; See also Sullivan et al., 
supra note 68, at 442, 447 (comparing patterns of opioid use in a privately insured population and a 
Medicaid population and finding that the “rates of opioid use were markedly higher” among the 
Medicaid population). Specifically, Medicaid patients were more likely to be prescribed opioids and 
more likely to receive a longer total supply, a higher cumulative yearly dose, and a greater number of 
opioid prescriptions. Id. at 447.  
71 Prescription Opioids: Risk Factors, supra note 70 (footnotes omitted). High daily opioid dose is 
considered “a prescribed daily dose of 100 morphine milligram equivalents (MME) or greater.” Karin A. 
Mack et al., Prescription Practices Involving Opioid Analgesics Among Americans with Medicaid, 
2010, 26 J. HEALTH CARE FOR POOR & UNDERSERVED 182, 185 (2015); see also id. at 183–88 
(analyzing 2010 prescription claims data and finding seventeen percent of a study population of 359,368 
Medicaid beneficiaries were prescribed high daily doses of opioids “at least once during the study 
period,” and of those beneficiaries, “[seventeen percent] had [high] daily doses . . . for more than 90 
days”); Yang et al., supra note 70, at 449 (finding that twenty-eight percent of Medicaid beneficiaries 
with overlapping prescriptions and twenty-four percent of those with pharmacy shopping and 
overlapping prescriptions were prescribed high daily doses). Sullivan et al. found that “cumulative opioid 
dose per day supplied was similar” between Medicaid and privately insured populations, but that 
Medicaid beneficiaries received “more prescriptions and higher opioid doses per prescription.” Sullivan 
et al., supra note 68, at 445–46. 
72 Prescription Opioids: Risk Factors, supra note 70 (footnotes omitted); see GAO: BEHAVIORAL 
HEALTH, supra note 38, at 1–2 (stating that in comparison to privately insured persons, Medicaid 
beneficiaries have “a higher rate of behavioral health conditions,” which include mental health and 
substance use conditions).  
73 Prescription Opioids: Risk Factors, supra note 70 (footnotes omitted). Living in a rural area and 
having low income are interconnected. See Vann R. Newkirk II & Anthony Damico, The Affordable 
Care Act and Insurance Coverage in Rural Areas, KAISER COMM’N ON MEDICAID & THE 
UNINSURED 1 (May 2014), https://kaiserfamilyfoundation.files.wordpress.com/2014/05/8597-the-
affordable-care-act-and-insurance-coverage-in-rural-areas1.pdf [https://perma.cc/KJ2E-9FSS] (stating 
that approximately sixteen percent of the U.S. population lives in rural areas and that rural areas have 
higher shares of “low-to-moderate income individuals”). Persons with incomes below 138% of the 
federal poverty level are considered low-income, which is also the income threshold to qualify for 
Medicaid in expansion states. GAO: BEHAVIORAL HEALTH, supra note 38, at 4. Approximately 25% 
of those living in rural areas have incomes below the FPL. See Newkirk & Damico, supra, at 1.  
74 Mack et al., supra note 70, at 183, 195. In this study, indicators of “potential misuse or 
inappropriate prescription practices,” included: (1) “opioid overlap,” or opioid prescriptions overlapping 
seven or more days; (2) “opioid and benzodiazepine overlap,” or prescriptions of opioids and 
benzodiazepine overlapping seven or more days; (3) “high daily opioid dose”; and, (4) “rapid opioid dose 
escalation,” or “having a 50% or greater increase in mean MMEs per month twice consecutively during 
the year.” Id. at 185. In addition to “increased numbers of opioid prescriptions,” each of the indicators 
measured has been associated with “increased risk of clinically recognized abuse.” Id. at 195 (footnotes 
omitted). In Mack et al., approximately 40% of the study population of Medicaid beneficiaries had at 
least one indicator of potential inappropriate use or prescribing. Id. at 188.  
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addition to demographic characteristics that make the Medicaid population more 
vulnerable to opioid use disorder, “inappropriate prescribing practices and opioid 
prescribing rates are [also] substantially higher among Medicaid patients.”75 
The underlying risk factors associated with one’s Medicaid status also make 
Medicaid beneficiaries more susceptible to nonmedical use of opioids and the 
corresponding adverse consequences of such use. Compared to privately insured opioid 
users, users in the Medicaid population have a higher prevalence of opioid use disorders 
and a higher frequency of nonmedical use, placing them at greater risk of being high-
intensity opioid users.76 Not surprisingly, Medicaid beneficiaries are also most 
susceptible to developing heroin abuse or dependence.77 But, in addition to risks of  
high-intensity use, the Medicaid population disproportionately suffers from complex 
physical and mental health conditions,78 such as other drug or alcohol disorders or 
mental health illnesses, which are strongly associated with nonmedical opioid use and 
opioid use disorder.79  
Thus, the adverse health outcomes stemming from the increasing use of opioids 
can only partially be explained by harmful prescribing practices and the addictive 
characteristics of opioids. Efforts to curb opioid use disorder among the Medicaid 
population require strategies that account for the complex interaction between the 
baseline risks of initiating treatment with opioids and the socioeconomic factors 
predisposing Medicaid beneficiaries to worse health outcomes.  
 
II.  ADDRESSING OPIOID MISUSE, OVERDOSE, AND ADDICTION THROUGH 
MEDICATION ASSISTED TREATMENT 
 
A.  Proposed Solutions for Addressing Opioid-Related Morbidity and Mortality 
 
Because worsening health outcomes associated with opioid consumption have 
predominantly been attributed to the exponential growth in prescribing rates, 
efforts to alleviate the harmful effects of opioid misuse have focused on controlling 
the prescription and supply of opioids. For instance, almost all states have 
implemented prescription drug monitoring programs (PDMPs), state-based 
                                                                                                                                                                           
75 Prescription Opioids: Risk Factors, supra note 70.  
76 Han et al., supra note 51, at 1470, 1472, 1476. 
77 New Research Reveals the Trends and Risk Factors Behind America’s Growing Heroin 
Epidemic, supra note 37.  
78 See KAISER COMM’N ON MEDICAID & THE UNINSURED, Medicaid: A Primer, 1, 3, 10, 21 (Mar. 
2013), http://kaiserfamilyfoundation.files.wordpress.com/2010/06/7334-05.pdf [https://perma.cc/QWZ7-
AAFV] (providing an overview of the complex health care needs of Medicaid beneficiaries).  
79 See Jones, supra note 51, at 233–34 (“[P]eople with opioid analgesic abuse or dependence are 
using other substances in high-risk ways . . . with [greater than one in three] having past-year alcohol 
abuse or dependence and nearly [one] in [five] having past-year marijuana or prescription sedative or 
tranquilizer abuse or dependence.”); id. at 234 (citations omitted) (using multiple substances is a “risk 
factor for overdose death”); Saha et al., supra note 51, at 775 (noting that nonmedical use of opioids and 
opioid disorder were “strongly related” to other mental health and substance disorders).  
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electronic databases that track the dispensation of prescription drugs and store 
individual patient data to identify patients at risk of inappropriate use or overdose.80 
Similarly, several states and professional organizations have developed prescribing 
guidelines to educate providers on the risk of prescribing opioids, provide 
appropriate dosing thresholds, and recommend strategies to identify and minimize 
patient misuse.81 But, solutions targeting only supply side issues neglect patient 
characteristics that drive one’s demand for opioids. 82  
While primary prevention strategies83 may reduce opioid use and abuse among 
persons who have not previously used opioids or diminish access to those at higher risk of 
overdose, such strategies are inadequate for dealing with the large number of persons 
already dependent on prescription opioids or heroin.84 An effective public health response 
to the opioid epidemic must combine primary, secondary, and tertiary prevention 
strategies to: (1) prevent development of new cases of opioid use disorder; (2) identify  
high-risk patients and treat opioid-addicted patients before serious complications arise; 
and, (3) provide effective addiction treatment to those already suffering from opioid use 
disorder.85  
Although states seem to be actively pursuing interventions addressing opioid 
prescribing, they are largely failing at expanding access to MAT, with one report 
finding that merely three states had adequate capacity to provide MAT to residents 
with opioid dependence.86 Not surprisingly, there is a significant discrepancy 
between the number of patients needing treatment and a state’s capacity to deliver 
treatment, leaving over 1.5 million of the 2.5 million Americans suffering from 
opioid abuse or dependence without treatment.87 The dire need for substance abuse 
                                                                                                                                                                           
80 ASPE ISSUE BRIEF ON OPIOID ABUSE 2015, supra note 7, at 4; Deborah Dowell et al., 
Mandatory Provider Review and Pain Clinic Laws Reduce the Amounts of Opioids Prescribed and 
Overdose Death Rates, 35 HEALTH AFF. 1876, 1876 (2016).  
81 See Dowell et al., supra note 11, at 2–3.  
82 Wilson M. Compton et al., Prescription Opioid Abuse: Problems and Responses, 80 
PREVENTIVE MED. 5, 6 (2015). 
83 Primary prevention efforts are designed to decrease the incidence of a disease or condition. 
Kolodny et al., supra note 5, at 565.  
84 Dowell et al., supra note 80, at 1881–82.  
85 Kolodny et al., supra note 5, at 565–68. Secondary prevention “screen[s] for a health condition 
after its onset but before it causes serious complications.” Id. at 567. Tertiary prevention “involve[s] both 
therapeutic and rehabilitative measures once a disease is firmly established.” Id. at 568. In the context of 
opioid addiction, the goal of tertiary prevention is to “prevent overdose deaths, medical complications, 
psychosocial deterioration, transition to injection drug use, and injection-related infectious diseases.” Id.  
86 See NAT’L SAFETY COUNCIL, PRESCRIPTION NATION 2016: ADDRESSING AMERICA’S DRUG 
EPIDEMIC 13–15, http://www.nsc.org/RxDrugOverdoseDocuments/Prescription-Nation-2016-American-
Drug-Epidemic.pdf [https://perma.cc/TNS2-XTGC] (last visited Nov. 4, 2017) (examining the number of 
states that satisfied six indicators thought to be critical in effectively addressing opioid epidemic). A majority of 
states met indicators relating to prescription drug monitoring programs and prescription of naloxone, while the 
fewest number of states met requirements for availability of opioid use disorder treatment. Id.  
87 Christopher M. Jones et al., National and State Treatment Need and Capacity for Opioid Agonist 
Medication-Assisted Treatment, 105 AM. J. PUB. HEALTH e55, e57 (2015), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504312/pdf/AJPH.2015.302664.pdf [https://perma.cc/F574-
RSA8]; Nora D. Volkow et al., Medication-Assisted  
Therapies — Tackling the Opioid-Overdose Epidemic, 370 NEW ENG. J. MED. 2063, 2064 (2014), 
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treatment is further illustrated by the rapidly growing number of deaths involving 
heroin,88 which opioid abusers often transition to because of its lower price and 
increased accessibility.89 Therefore, truly impacting opioid-related morbidity and 
mortality requires acknowledgment of underlying substance use disorder and 
subsequently expanding access to treatment.  
 
B.  Overview of Medication Assisted Treatment 
 
Opioids are highly addictive because of their ability to suppress feelings of pain 
and induce euphoria.90 Repeated exposure to opioids produces structural and 
functional changes in the brain that result in dependence or subsequently addiction, 
which causes persons to experience severe withdrawal symptoms when they reduce 
or stop using the drug.91 Treating opioid use disorder is difficult for several reasons, 
including “the relapsing nature of [the] condition, the frequent presence of 
psychiatric and medical comorbidities, and the disproportionate impact on those in 
socioeconomically disadvantaged settings with limited access to care.”92 The most 
effective substance abuse treatments provide a comprehensive set of services, 
including “medical, social, psychological, and rehabilitative” components designed 
to address the complex care needs of patients.93  
                                                                                                                                                                           
http://www.nejm.org/doi/pdf/10.1056/NEJMp1402780 [https://perma.cc/EY5H-QUZB]. Approximately 1.9 
million of the 2.5 million are addicted to opioid painkillers. NAT’L SAFETY COUNCIL, supra note 86, at 8. Rates 
of opioid abuse and dependency far exceed maximum treatment capacity. Id. at 26.  
88 See Rudd et al., supra note 2, at 1445–46; New Research Reveals the Trends and Risk Factors 
Behind America’s Growing Heroin Epidemic, supra note 37.  
89 Theodore J. Cicero et al., The Changing Face of Heroin Use in the United States: A 
Retrospective Analysis of the Past 50 Years, 71 JAMA PSYCHIATRY 821, 825 (2014), 
http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1874575 [https://perma.cc/8LGN-WPFD] 
(follow “Download PDF” hyperlink). Dependence on prescription opioids is strongest risk factor for 
heroin abuse or dependence); New Research Reveals the Trends and Risk Factors Behind America’s 
Growing Heroin Epidemic, supra note 37.  
90 Kolodny et al., supra note 5, at 560; Misuse of Prescription Drugs, Opioids, NAT’L INST. ON DRUG 
ABUSE, https://www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs/which-classes-
prescription-drugs-are-commonly-misused [https://perma.cc/FS99-7WP5] (last updated Aug. 2016).  
91 Misuse of Prescription Drugs, Opioids, supra note 90.Withdrawal symptoms include: “yawning 
and other sleep problems, sweating more than normal, anxiety or nervousness, muscle aches and pains, 
stomach pain, nausea, or vomiting, diarrhea, and weakness.” U.S. DEP’T OF HEALTH & HUMAN 
SERVS. & SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., Medication-Assisted Treatment 
for Opioid Addiction: Facts for Families & Friends 1, 9 (2014) [https://perma.cc/N3BB-9WXP]. 
92 ROGER CHOU ET AL., AGENCY FOR HEALTHCARE RESEARCH & QUALITY, TECHNICAL 
BRIEF NO. 28, PUB. NO. 16(17)-EHC039-EF, MEDICATION-ASSISTED TREATMENT MODELS OF 
CARE FOR OPIOID USE DISORDER IN PRIMARY CARE SETTINGS 1 (Dec. 2016) (footnotes omitted) 
https://ahrq-ehc-application.s3.amazonaws.com/media/pdf/opioid-use-disorder_technical-brief.pdf 
[https://perma.cc/W2B9-ZQY4].  
93 U.S. DEP’T OF HEALTH & HUMAN SERVS., Addressing Prescription Drug Abuse in the United 
States: Current Activities and Future Opportunities 31, 
https://www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf 
[https://perma.cc/T7LY-ZC47] (last visited Nov. 4, 2017).  
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MAT is a “whole-patient approach”94 to substance abuse treatment that 
combines the use of three FDA-approved medications, methadone, buprenorphine, 
or naltrexone,95 with behavioral therapies to “reestablish normal brain functioning, 
reduce cravings, and prevent relapse.”96 The medication component “block[s] the 
euphoric . . . effects of opioids, reduce[s] the craving for opioids, and . . . 
mitigate[s] the symptoms of withdrawal,” facilitating the patient’s ability to engage 
in behavioral therapies, which “address the psychosocial contributors to [opioid use 
disorder,] . . . improve retention in care[,]”97 and promote positive lifestyle 
changes.98 To be effective, MAT should be provided in a “clinically-driven, person-
centered, and individualized setting,”99 capable of managing patients’ comorbid 
physical and mental conditions.100 In fact, a study examining the efficacy of 
buprenorphine or methadone treatment among Medicaid patients diagnosed with 
opioid abuse or dependence found that inadequate management of patients’ 
preexisting substance abuse and mental health conditions was associated with 
significantly higher treatment costs and rates of relapse.101  
Thus, the benefit of MAT is dependent upon the ability to provide treatment 
that simultaneously addresses the totality of a patient’s comorbid substance use 
disorders and mental health problems.102 Unfortunately, societal misunderstanding 
regarding MAT and opioid dependence and the laws regulating the provision of 
MAT, has created a delivery system that is not only inadequate to satisfy current 
demand for treatment but also incapable of providing coordinated, comprehensive 
services adequate to meet patients’ complex health care needs.103 
                                                                                                                                                                           
94 CMS Best Practices for Addressing Prescription Opioid Overdoses, Misuse, & Addiction, supra 
note 33, at 13.  
95 The FDA has approved three medications for treating opioid use disorders: (1) methadone, (2) 
buprenorphine, and (3) naltrexone. CMCS Informational Bulletin from Dirs. and Adm’rs of Various 
Pub. Health-Related Fed. Agencies on Medication Assisted Treatment, supra note 18, at 3–4. The 
medication selected for treatment depends upon the severity of the patient’s opioid use disorder, but 
generally each medication is used to reduce or eliminate the patient’s withdrawal symptoms. See Kyle 
Kampman & Margaret Jarvis, American Society of Addiction Medicine (ASAM) National Practice 
Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use, 9 J. 
ADDICTION MED. 358, 361–63 (2015). 
96 CMCS Informational Bulletin from Dirs. and Adm’rs of Various Pub. Health-Related Fed. 
Agencies on Medication Assisted Treatment, supra note 18, at 2 (footnote omitted).  
97 CHOU ET AL., supra note 92, at 1–2; see also CMCS Informational Bulletin from Dirs. and 
Adm’rs of Various Pub. Health-Related Fed. Agencies on Medication Assisted Treatment, supra note 
18, at 2 (footnote omitted) (discussing the use of medication to allow utilization of behavioral therapy). 
98 U.S. DEP’T OF HEALTH & HUMAN SERVS. & SUBSTANCE ABUSE & MENTAL HEALTH 
SERVS. ADMIN., supra note 91, at 4–5.  
99 CHOU ET AL., supra note 92, at 1 (footnote omitted).  
100 See CHOU ET AL., supra note 92, at 11; Clark et al., supra note 38, at 78.  
101 Clark et al., supra note 38, at 76–78.  
102 See id. at 77–78. 
103 Id. at 78; see KENNETH B. STOLLER ET AL., AM. ASS’N FOR THE TREATMENT OF OPIOID 
DEPENDENCE, INTEGRATED SERVICE DELIVERY MODELS FOR OPIOID TREATMENT PROGRAMS IN AN 
ERA OF INCREASING OPIOID ADDICTION, HEALTH REFORM, AND PARITY 1–2 (July 13, 2016), 
http://www.aatod.org/wp-content/uploads/2016/07/2nd-Whitepaper-.pdf [https://perma.cc/78MB-SJD9] 
(calling for integrated service delivery among opioid treatment programs, medical providers, and behavioral 
health providers).  
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C.  Barriers to the Expansion of Medication Assisted Treatment  
 
Despite evidence that MAT is an effective, safe, and cost-saving measure to 
help patients recover from opioid use disorder and reduce the risk of other health 
conditions associated with drug abuse, several barriers have limited access to and 
use of MAT.104  
 
i.  Stigmatization of Opioid Dependence and Medication Assisted Treatment 
 
Deeply rooted societal misconceptions have led to the characterization of drug 
dependence and addiction as an individual’s moral problem or willful choice rather 
than a medical condition.105 In fact, there are no health conditions associated with 
more “social disapproval and discrimination” than drug dependence.106 Personally 
faulting individuals with drug dependence rather than embracing addiction as a 
chronic medical disorder, such as asthma, diabetes, or hypertension,107 has far 
reaching detrimental effects including: (1) serving as “a major obstacle to personal 
and family recovery, [(2)] contribut[ing] to the marginalization of addiction 
professionals[,] . . . and [(3)] limit[ing] the type and magnitude  
of . . . resources allocated to . . . drug-related problems.”108  
In addition to the social stigma directed toward addicted individuals, MAT itself is 
tainted by the perception that the medication component “merely replace[s] one addiction 
with another.”109 This misconception has produced skepticism among medical providers 
                                                                                                                                                                           
104 Onur Baser et al., Cost and Utilization Outcomes of Opioid-Dependence Treatments, 17 AM. J. MANAGED CARE 
S235, S245–47 (2011), http://www.ajmc.com/journals/supplement/2011/a369_june11/a369_11jun_alcohol_s235to48/P-4 
[https://perma.cc/R2WP-HH4F] (follow “PDF” hyperlink); Volkow et al., supra note 87, at 2064–65. 
105 Yngvild Olsen & Joshua M. Sharfstein, Opinion, Confronting the Stigma of Opioid Use Disorder and Its 
Treatment, 311 JAMA 1393, 1393 (2014), http://jamanetwork.com/journals/jama/article-abstract/1838170 
[https://perma.cc/THS9-J5UU] (follow “Download PDF” hyperlink); WILLIAM L. WHITE, LONG-TERM 
STRATEGIES TO REDUCE THE STIGMA ATTACHED TO ADDICTION, TREATMENT, AND RECOVERY WITHIN 
THE CITY OF PHILADELPHIA 11–12 (2009), http://www.williamwhitepapers.com/pr/2009Stigma%26methadone.pdf 
[https://perma.cc/689B-HZDP]; see also Compton et al., supra note 82, at 6 (“Opioid use disorder is a neurobiological 
disorder that produces well defined changes to the reward circuitry within the brain and a severe withdrawal syndrome that 
can make it very difficult to recover.”); WHITE, supra, at 9 (footnote omitted) (“Stigma is the experience of being ‘deeply 
discredited’ due to one’s ‘undesired differentness.’ To be stigmatized is to be held in contempt, shunned, or rendered socially 
invisible because of a socially disapproved status.”).  
106 WHITE, supra note 105, at 9–10 (footnote omitted).  
107 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., HHS PUB. NO. 12-4214, MEDICATION-ASSISTED 
TREATMENT FOR OPIOID ADDICTION IN OPIOID TREATMENT PROGRAMS: A TREATMENT IMPROVEMENT 
PROTOCOL TIP 43, at 3 (2017), https://www.ncbi.nlm.nih.gov/books/NBK64164/pdf/Bookshelf_NBK64164.pdf 
[https://perma.cc/R8AL-5C4G].  
108 WHITE, supra note 105, at 2. 
109 Volkow et al., supra note 87, at 2065; JOHNS HOPKINS BLOOMBERG SCH. OF PUB. HEALTH, 
THE PRESCRIPTION OPIOID EPIDEMIC: AN EVIDENCE-BASED APPROACH 41 (Nov. 2015), 
https://www.jhsph.edu/research/centers-and-institutes/center-for-drug-safety-and-
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and a tendency for addiction treatment facilities to favor abstinence models,110 which are 
less effective than MAT in “reducing the frequency and quantity of opioid  
use[,] . . . [diminishing] risk of overdose, [and] improving social functioning.”111 In fact, 
compared to “time-limited medication . . . or psychosocial and abstinence 
interventions,”112 the combination of counseling and medication through MAT “is more 
effective at treatment retention and reduction of heroin and prescription opiate abuse.”113 
Therefore, societal misunderstanding, among both the general population and health care 
providers, regarding the benefits of MAT seems to be a continuing obstacle in expanding 
access to MAT.  
 
ii.  Legal Framework Regulating the Provision of Medication Assisted Treatment 
 
Outside of pervasive societal stigmatization, federal and state regulation of the 
medications used in MAT, specifically, methadone and buprenorphine, has also 
significantly affected the availability of MAT. Because methadone and 
buprenorphine are controlled substances,114 they are subject to the Controlled 
Substances Act (CSA),115 which imposes strict requirements when these 
medications are prescribed and used for opioid addiction treatment.116  
Following passage of the CSA, physicians could prescribe methadone for opioid 
addiction for the first time but subject to significant limitations.117 Under the CSA, 
methadone is considered a Schedule II drug118 and therefore can only legally be 
                                                                                                                                                                           
effectiveness/research/prescription-opioids/JHSPH_OPIOID_EPIDEMIC_REPORT.pdf 
[https://perma.cc/9XGQ-TB5Y]. 
110 Volkow et al, supra note 87, at 2065; see also CHOU ET AL., supra note 92, at 27 (highlighting 
the “pervasive” stigma toward MAT among “physicians, clinic staff, patients, law enforcement, 
policymakers, insurers, and the community”).  
111 AGENCY FOR HEALTHCARE RESEARCH & QUALITY, supra note 55, at 1. 
112 Time limited medications are those used in detoxification or tapering. Mary Kate Mohlman et 
al., Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and 
Health Services Utilization Rates in Vermont, 67 J. SUBSTANCE ABUSE TREATMENT 9, 10 (2016) 
http://www.journalofsubstanceabusetreatment.com/article/S0740-5472(15)30065-9/pdf 
[https://perma.cc/9T8Q-ZFV5]. 
113 Id.; see also CMCS Informational Bulletin from Dirs. and Adm’rs of Various Pub. Health-
Related Fed. Agencies on Medication Assisted Treatment, supra note 18, at 5 (“Research shows that 
when treating SUDs, a combination of medication and behavioral therapies is the most effective.”).  
114 A controlled substance is “a drug or other substance, or immediate precursor,” included in 
schedules I, II, III, IV, or V of the Controlled Substances Act. 21 U.S.C. § 802(6) (2012).  
115 See generally 21 U.S.C. §§ 801–890, 901–904, 951–971 (2012).  
116 U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID ADDICTION: LAWS, 
REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED TREATMENT 
ACCESS 5–8, 7 n.8 (2016), http://www.gao.gov/assets/690/680264.pdf [https://perma.cc/XY9Z-Y5A5]. 
117 Id. at 10–13 (discussing the significant limitations the CSA placed on physicians ability to 
prescribe methadone); Barnes & Worthy, supra note 22, at 564 (citing Comprehensive Drug Abuse 
Prevention and Control Act of 1970, Pub. L. No. 91–513, 84 Stat. 1236 (codified as amended at 21 
U.S.C. §§ 801– 852 (2011))).  
118 Schedule II drugs have the “highest potential for abuse among scheduled drugs with an accepted 
medical use;”; abuse of Schedule II drugs may result in “severe psychological or physical dependence.” 
U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID ADDICTION: LAWS, REGULATIONS, 
AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED TREATMENT ACCESS at 6–7 (2016).  
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administered or dispensed in an opioid treatment program (OTP),119 a practitioner 
or facility certified by Substance Abuse and Mental Health Services Administration 
(SAMSHA) and registered by the Drug Enforcement Administration (DEA) to 
provide opioid treatment.120 To receive SAMSHA certification, an OTP must 
meet federal opioid treatment standards, which specify the patients that are eligible 
to receive treatment and the services that must be provided, including: “medical, 
counseling, vocational, educational, and other assessment and treatment 
services.”121 In addition to restrictions on location, only practitioners who obtain 
separate OTP registration may administer or dispense methadone.122 Not 
surprisingly, the highly regulated nature of methadone treatment has produced 
significant barriers to access, including “waiting lists for treatment entry, limited 
geographic coverage, limited insurance coverage, and the requirement that many 
patients receive methadone at the OTP daily.”123  
In contrast to methadone, buprenorphine is a Schedule III drug124 and is subject 
to less stringent limitations. Although buprenorphine can also be prescribed in 
OTPs, the Drug Addiction Treatment Act of 2000 (DATA)125 expanded access to 
buprenorphine by allowing qualified physicians to obtain waivers (DATA waivers) 
from the CSA to dispense or prescribe buprenorphine in an outpatient setting.126 
Among other requirements, obtaining a waiver requires a practitioner to have the 
capacity to directly provide or refer patients to appropriate counseling services.127 
                                                                                                                                                                           
119 42 C.F.R. § 8 (2017).  
120 U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID ADDICTION: LAWS, 
REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED TREATMENT 
ACCESS  
10–12 (2016).  
121 42 C.F.R. § 8.12 (2017); U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID 
ADDICTION: LAWS, REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED 
TREATMENT ACCESS 12 (2016).  
122 U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID ADDICTION: LAWS, 
REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED TREATMENT 
ACCESS 10 (2016).  
123 Jones et al., supra note 87, at e55 (footnotes omitted). As of July 2016, there were approximately 
“1,400 OTPs in the [U.S.], treating approximately 350,000 patients” daily. STOLLER ET AL., supra note 
103, at 1. OTPs operate in all states except North Dakota and Wyoming. Jones et al., supra note 87, at 
e59–60.  
124 Schedule III drugs have an accepted medical use and less potential for abuse than drugs in 
Schedules I and II, but “abuse of [Schedule III] drug[s] may lead to moderate or low physical 
dependence or high psychological dependence.” U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-
833, OPIOID ADDICTION: LAWS, REGULATIONS, AND OTHER FACTORS CAN AFFECT 
MEDICATION-ASSISTED TREATMENT ACCESS 6 (2016).  
125 Children’s Health Act of 2000, Pub. L. No. 106–310, § 3502, 114 Stat. 1101, 1222–27 (codified 
as amended at 21 U.S.C. § 823(g)).  
126U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-16-833, OPIOID ADDICTION: LAWS, 
REGULATIONS, AND OTHER FACTORS CAN AFFECT MEDICATION-ASSISTED TREATMENT 
ACCESS 13 (2016); Jones et al., supra note 87, at e55. 
127 21 U.S.C. § 823(g)(2)(B)(ii) (2012).  
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Originally, the DATA allowed physicians to prescribe buprenorphine to up to 
thirty patients,128 but the law was later amended to allow physicians who had been 
prescribing for one year to submit a revised waiver to treat up to 100 patients.129 
Most recently, eligibility for DATA waivers was extended to qualifying nurse 
practitioners and physicians’ assistants130 and the patient capitation limit was raised 
to 275 patients for certain physicians; 131 both changes are expected to further 
enhance providers’ ability to provide MAT with buprenorphine.132 Yet, the drastic 
growth in treatment capacity through buprenorphine and DATA-waived 
physicians has not produced a parallel reduction in the rates of opioid abuse and 
dependence, which continued to steadily rise over the course of these regulatory 
changes.133  
Though the effect of the most recent modifications remains to be seen, prior 
data illustrate that even the most recent modifications facilitating the prescription 
of buprenorphine may have a minimal impact on patient access to MAT. For 
instance, as of 2012, six years after the patient limit was increased to 100 patients, 
only 28% of DATA-waived physicians nationwide had patient limits of 100, and 
no state had more than 45% of DATA-waived physicians at the 100-patient 
limit.134 Moreover, studies have found that an estimated 34% to 56% of physicians 
with waivers do not actually prescribe buprenorphine; and, of the physicians that do 
prescribe buprenorphine, the majority do not reach their patient limit.135 The more 
lenient regulation of buprenorphine has also had a limited effect on OTPs.136 The 
majority of OTPs continue to provide only methadone treatment,137 despite the 
fact that OTPs are not subject to limitations on the number of patients who can 
receive buprenorphine prescriptions.138  
Overall, the marginal impact of regulation enabling the prescription of 
buprenorphine is concerning for several reasons. First, it demonstrates that even a 
dramatic increase in treatment capacity may be insufficient to alleviate the 
                                                                                                                                                                           
128 Id. § 823(g)(2)(B)(iii) (2000) (amended 2006). 
129 Id. § 823(g)(2)(B)(iii) (2012).  
130 Comprehensive Addiction and Recovery Act of 2016, Pub. L. No. 114–198, § 303(a)(1), 130 
Stat. 695, 720–22. 
131 42 C.F.R. § 8.610 (2017).  
132 Charles Townley & Hannah Dorr, Integrating Substance Use Disorder Treatment and Primary 
Care, NAT’L ACAD. FOR STATE HEALTH POLICY 5–6 (Feb. 2017), http://nashp.org/wp-
content/uploads/2017/02/Primary-Care-Integration-Brief.pdf [https://perma.cc/NB4Y-PY66]; see also 
21 U.S.C. § 823(g)(2)(B)(iii) (2012) (giving SAMSHA the authority to increase patient limits).  
133 See Jones et al., supra note 87, at e57–e58. For an illustration of the changes in opioid abuse or 
dependence and treatment capacity, see Table 1 and Figure 1 on e57 and e58, respectively. 
134 Id. at e59, Table 2.  
135 Id. at e55.  
136 Id. at e60.  
137 Id. (citing SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., HHS PUB. NO. 14-
4807, 2011 OPIOID TREATMENT PROGRAM SURVEY: DATA ON SUBSTANCE ABUSE TREATMENT 
FACILITIES WITH OTPS 71 (Aug. 2013), 
https://www.samhsa.gov/data/sites/default/files/OTP2011_Web/OTP2011_Web/OTP2011_Web.pdf 
[https://perma.cc/68VB-E5S9].  
138 Jones et al., supra note 87, at e60.  
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discrepancy between the need for and receipt of treatment for opioid use 
disorder.139 Second, it indicates that reducing opioid-related morbidity and 
mortality cannot be achieved merely through expanding access to treatment, 
whether by raising patient capitation limits or allowing more types of providers to 
prescribe buprenorphine.  
While stricter regulations may more harshly affect access to MAT with 
methadone, pervasive barriers, including “provider  
availability[,] . . . willingness to prescribe, . . . low provider confidence in addressing 
addiction, limited access to addiction experts, lack of institutional or office support, 
lack of behavioral health services, and reimbursement concerns,”140 also plague 
access to buprenorphine. Thus, it seems that factors beyond stringent laws 
regulating the administration and prescription of medications used in MAT 
underlie the problems with patient access. 
Although laws restricting the dispensation of methadone and buprenorphine 
have contributed to the gap between treatment need and capacity, strategies to 
improve the delivery of MAT exist within our current legal framework. Merely 
expanding treatment capacity will not overcome the cumulative effects of societal 
stigma and the laws regulating addiction treatment, which over time have severed 
substance abuse treatment from the mainstream health care system.141 Because the 
efficacy of MAT, especially among Medicaid beneficiaries, is largely dependent 
upon management of a patient’s comorbid conditions, improving delivery of MAT 
requires solutions that enhance not only access to and use of MAT, but also 
provide coordinated care through a variety of treatment services.  
 
III.  MEDICAID HEALTH HOMES AND THE PROVISION OF MEDICATION 
ASSISTED TREATMENT 
 
A.  Current State of Medicaid Coverage of Medication Assisted Treatment 
 
Because of Medicaid beneficiaries’ increased susceptibility to opioid use 
disorder and the Medicaid program’s augmented role in financing substance abuse 
under the ACA, states have a significant interest in understanding how the 
provision of MAT will impact not only total health care expenditures, but also the 
health outcomes of their beneficiaries.142 States’ Medicaid policies vary widely on 
the coverage of and limits placed on MAT, but over the last decade there has been 
                                                                                                                                                                           
139 See id. at e57 (noting that the “marked[]” increase in treatment capacity did not significantly 
close the “gap in treatment need and capacity”).  
140 Id. at e55.  
141 See Buck, supra note 20, at 1402 (noting that “treatment of substance abuse disorders occurs 
predominantly in a separate specialty services sector”); Olson & Sharfstein, supra note 105, at 1393–94 
(stating that one factor impeding expansion of MAT is “the separation of opioid use disorder treatment 
from the rest of health care”).  
142 Mohlman et al., supra note 112, at 10.  
                                            KENTUCKY LAW JOURNAL                                        Vol. I06 132
a general shift toward policies favoring coverage of the medications involved in 
MAT.143 Studies analyzing the availability of medications and the characteristics of 
benefit designs in states’ Medicaid programs often cite the following elements as 
barriers to MAT access: (1) the preferred drug list,144 (2) prior authorization,145  
(3) quantity and duration limits,146 and (4) behavioral health requirements.147 
Regardless of the way a state organizes the delivery of MAT to its beneficiaries, the 
specific elements of each state’s benefit design will undoubtedly affect cost, access, 
and use of MAT. While being mindful of these baseline variances in states’ MAT 
coverage, this Note will focus more on the infrastructure of Vermont’s delivery 
system and whether this framework, which integrates OTPs and buprenorphine 
prescribing physicians to provide two tiers of patient care,148 will be a feasible 
model for other states.  
 
 
 
                                                                                                                                                                           
143 Rachel M. Burns et al., Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: 
The Evolution of State Policies from 2004 to 2013, 37 SUBSTANCE ABUSE 63, 65 (2015), 
http://www.tandfonline.com/doi/pdf/10.1080/08897077.2015.1080208?needAccess=true 
[https://perma.cc/YY3F-BSWS]. 
144 A Medicaid agency’s preferred drug list designates drugs as either preferred or  
non-preferred. CMCS Informational Bulletin from Dirs. and Adm’rs of Various Pub.  
Health-Related Fed. Agencies on Medication Assisted Treatment for Substance Abuse Disorders, supra 
note 18, at 7. Preferred drugs can be prescribed without prior authorization for payment coverage, while 
non-preferred drugs cannot. Id.; see Burns et al., supra note 143, at 65 (finding that not all states cover 
both methadone and buprenorphine); Mark et al., supra note 36, at 3 (urging states to reassess their 
preferred drug lists to cover more medications used to treat opioid addiction); SUBSTANCE ABUSE & 
MENTAL HEALTH SERVS. ADMIN., HHS PUB. NO. SMA-14-4854, MEDICAID COVERAGE AND 
FINANCING OF MEDICATIONS TO TREAT ALCOHOL AND OPIOID USE DISORDERS 17–18, 45–62 
(2014), http://store.samhsa.gov/shin/content/SMA14-4854/SMA14-4854.pdf 
[https://perma.cc/7GYX-MX7H] (depicting availability of medications on each states’ preferred drug 
list).  
145 Prior authorization signifies that a “prescriber must obtain permission from Medicaid or the 
agency’s vendor.” CMCS Informational Bulletin from Dirs. and Adm’rs of Various Pub. Health-
Related Fed. Agencies on Medication Assisted Treatment for Substance Use Disorders, supra note 18, 
at 7; see Burns et al., supra note 143, at 66 (warning that prior authorization can be a barrier to both 
providers and patients); Mark et al., supra note 36, at 3 (noting that prior authorization can be helpful 
for ensuring lower cost medications are tried first, but cautioning that prior authorization can also “cause 
administrative burdens that reduce access to medications”); SUBSTANCE ABUSE & MENTAL HEALTH 
SERVS. ADMIN., supra note 144, at 28 (reiterating concerns about prior authorization).  
146 See Mark et al., supra note 36, at 3 (stating that durational or lifetime limits on addiction 
medications is inconsistent with the view that “[o]pioid addiction is considered a chronic disease” and 
generally inconsistent with medical evidence); id. at 4 (noting that limiting dosages may interfere with 
the efficacy of treatment).  
147 States may require documentation that beneficiaries receiving FDA-approved medications for 
addiction treatment have either been referred or have started receiving behavioral therapy along with 
their medication. CMCS Informational Bulletin from Dirs. and Adm’rs of Various Pub. Health-
Related Fed. Agencies on Medication Assisted Treatment, supra note 18, at 7; see Burns et al., supra 
note 143, at 66 (noting that counseling requirements may improve adherence to treatment, but also may 
deter initiation and continuance of treatment). 
148 Casper & Folland, supra note 50, at 5, 17–19.  
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B.  Features of a Medicaid Health Home 
 
Over time, laws regulating the dispensation of MAT medications have 
produced a fragmented delivery system for MAT, segregating substance abuse 
treatment from the overall health care system and creating explicit divisions among 
OTPs and other MAT providers.149 Not only has the current infrastructure for 
MAT proven inadequate to meet the demands of the growing number of opioid 
dependent patients, it is also not equipped to treat the complex health needs of 
those seeking MAT. This is significant for several reasons. First, from a population 
health standpoint, the growing number of persons suffering from opioid 
dependence is producing a parallel shift in the prevalence of heroin use and 
dependence.150 Second, from a cost perspective, expanding access to MAT is an 
extremely costly endeavor.151 Although it is likely that a state would be able to 
offset direct medication costs through a reduction in spending on other health care 
costs, such as inpatient and outpatient care,152 states have a strong incentive to 
implement MAT programs that successfully treat patients while conserving costs. 
The existing arrangement for providing MAT is not sustainable. But, by building 
integration and care coordination into the current delivery system, the Medicaid 
health home seems to offer a potential solution to the provision of MAT.  
The Medicaid health home is a care delivery model derived from the patient 
centered medical home (PCMH), an approach characterized by a dynamic patient-
physician relationship whereby the patient’s primary care physician directs, 
coordinates, and monitors the patient’s care across various medical disciplines and 
community-based services.153 Under the ACA, states have the option to create 
health homes through state plan amendments to provide medical care for three 
categories of beneficiaries: (1) persons suffering from at least two chronic 
conditions, (2) persons with one chronic condition and at risk of developing 
another, and (3) persons with “[one] serious and persistent mental health 
condition.”154 The “designated provider” of a patient’s care, or the central 
component of the health home, may be a single physician, a practice group, an 
                                                                                                                                                                           
149 Id. at 6; STOLLER ET AL., supra note 103, at 1.  
150 Richard C. Dart et al., Trends in Opioid Analgesic Abuse and Mortality in the United States, 
372 NEW ENG. J. MED. 241, 247 (2015), http://www.nejm.org/doi/pdf/10.1056/NEJMsa1406143 
[https://perma.cc/YM5E-M7YW]; Jones, supra note 51, at 233–34. 
151 See Baser et al., supra note 104, at S240, S243, S245–46 (comparing health care costs and 
utilization among patients receiving opioid-dependence treatment with or without medication and 
finding that total medication costs were significantly greater for those receiving medication); Mohlman 
et al., supra note 112, at 10 (noting that MAT is associated with significantly higher costs than 
“tapering, abstinence, or psychosocial interventions”).  
152 Baser et al., supra note 104, at S245–46; Mohlman et al., supra note 112, at 10.  
153 Amanda Cassidy, Patient-Centered Medical Homes, 29 HEALTH AFF., Sept. 14, 2010, at 1–2, 
http://www.healthaffairs.org/do/10.1377/hpb20100914.118477/full/healthpolicybrief_25.pdf 
[https://perma.cc/VF8S-PDBP]; KAISER, Medicaid Health Homes, supra note 40, at 4–5.  
154 42 U.S.C. § 1396w-4(a), (h) (2012). 
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entity, such as a community health center, or a “team of health care professionals,” 
including physicians, nurses, nutritionists, social workers, and other 
professionals.155 Regardless of provider type, health homes must provide six core 
services to eligible beneficiaries: “[1] comprehensive care management; [2] care 
coordination . . . ; [3] comprehensive transitional care . . . ; [4] patient and family 
support . . . ; [5] referral to community and social support services . . .; and [6] use 
of health information technology to link services . . . .”156 Ultimately, by devising 
individualized health care plans that “coordinate[] and integrate[] all clinical and 
non-clinical services and supports” necessary to meet the patient’s needs,157 health 
homes seek to improve health care outcomes and reduce the costs of caring for 
clinically complex patients.  
Most states exercising the Medicaid health home option have targeted chronic 
conditions and serious mental illness, but Vermont, Maryland, and Rhode Island 
created health homes specifically targeting beneficiaries with opioid dependence.158 
In all three states, OTPs serve as designated providers, operating as a central 
contact and referral point for patients.159 But, Vermont’s Hub and Spoke model is 
unique in that it integrates OTPs with buprenorphine prescribing health care 
providers to provide patients with two levels of care and ensure patients receive care 
appropriately tailored to the complexity of the patient’s addictions and other health 
conditions.160 Because opioid dependent Medicaid beneficiaries are likely to suffer 
from or develop comorbid physical and mental health conditions,161 the health 
home’s intricate coordination of “physical and behavioral health services” seems to 
offer an ideal mechanism through which MAT can be delivered.162 
 
C.  Vermont’s Response to the Opioid Drug Crisis and Features of Vermont’s 
Medicaid Health Home 
 
Over the last two decades, Vermont, has experienced an exponential rise in 
opioid-related morbidity and mortality,163 including most recently, a nearly 40% 
rise in heroin dependency.164 In 2012, despite consistent rankings as the “healthiest 
state” on various health measures, Vermont ranked 34th for the highest prevalence 
                                                                                                                                                                           
155 See id. § 1396w-4(a), (h)(5)–(7), for the types of providers and facilities that are considered 
health homes.  
156 Id. § 1396w-4(h)(4).  
157 KAISER, Medicaid Health Homes, supra note 40, at 6.  
158 CMS, Health Home Overview, supra note 43, at 1; Moses & Klebonis, supra note 34, at 1. 
159 Moses & Klebonis, supra note 34, at 1. 
160 Id. at 2, 5. 
161 See supra notes 38, 76–79 and accompanying text.  
162 Moses & Klebonis, supra note 34, at 1.  
163 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 10.  
164 See Mohlman et al., supra note 112, at 9–10; Thomas A. Simpatico, Vermont Responds to Its 
Opioid Crisis, 80 PREVENTIVE MED. 10, 10 (2015). 
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of non-medical pain reliever use.165 Among Vermont’s Medicaid population, those 
suffering from opioid addiction had health care costs three times higher than the 
state’s average Medicaid beneficiary, with only part of the cost differential 
attributable to the cost of opioid disorder treatment.166 Apart from treatment costs, 
opioid dependent beneficiaries also had higher rates of “co-occurring mental health 
and other health issues” and use of “emergency rooms, pharmacy benefits, and 
other health care services.”167 Furthermore, use of illicit opioids was a primary 
contributor to Medicaid beneficiaries’ drug overdoses.168  
Amid the growing problems of opioid dependence and the demand for opioid 
treatment, the shortcomings of Vermont’s existing MAT treatment system became 
evident.169 In Vermont, like other states, the divergent federal regulation of 
buprenorphine and methadone, created a “bifurcated system of administering and 
providing . . . pharmacotherapy,” leading to the development of several systemic 
treatment delivery problems.170 While methadone programs “provided 
comprehensive addiction services,” they failed to incorporate other mental and 
physical health services.171 Similarly, buprenorphine prescribing providers offered 
inadequate access to addiction treatment and mental health services.172 Ultimately, 
the existing system segregated methadone and buprenorphine prescribers and 
hindered communication between providers regarding patients they shared in 
common.173 Therefore, in 2013, Vermont implemented a statewide health home 
model to address the inadequacies of its MAT delivery system.174 Through the 
                                                                                                                                                                           
165 VT. AGENCY OF HUMAN SERVS., INTEGRATED TREATMENT CONTINUUM FOR SUBSTANCE 
USE DEPENDENCE “HUB/SPOKE” INITIATIVE—PHASE 1: OPIATE DEPENDENCE 1 (Jan. 2012), 
http://atforum.com/documents/HUBSPOKEBriefingDocV122112.pdf [https://perma.cc/8SCL-
JRFY]. 
166 Id.  
167 Id. 
168 Anne VanDonsel et al., Opioids in Vermont: Prevalence, Risk, and Impact, VT. DEP’T OF 
HEALTH 38 (Oct. 27, 2016), 
http://www.healthvermont.gov/sites/default/files/documents/2016/12/ADAP_Opioids_Prevalence_Ris
k_Impact.pdf [https://perma.cc/PKT8-Z2ZD]. 
169 See DEP’T OF VT. HEALTH ACCESS, VERMONT BLUEPRINT FOR HEALTH 2012 ANNUAL 
REPORT 44 (Feb. 15, 2013), http://www.leg.state.vt.us/reports/2013ExternalReports/287348.pdf 
[https://perma.cc/4SSG-7H89] (“Vermont’s treatment programs had waiting lists, the number of 
physicians treating Vermonters for opioid dependence declined, and nearly 200 Vermonters traveled out 
of state to receive care.”).  
170 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 12; see also DEP’T OF VT. HEALTH ACCESS, supra note 169, at 44.  
171 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 12; DEP’T OF VT. HEALTH ACCESS, supra note 169, at 45. 
172 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 12; DEP’T OF VT. HEALTH ACCESS, supra note 169, at 45. 
173 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 12–13; DEP’T OF VT. HEALTH ACCESS, supra note 169, at 45.  
174 DEP’T OF VT. HEALTH ACCESS, VERMONT BLUEPRINT FOR HEALTH 2013 ANNUAL REPORT 54 (Jan. 30, 
2014), 
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health home model, the state sought to “[(1)] [i]ncrease access to MAT[,] [(2)] 
[s]trengthen the connection between specialty substance abuse treatment clinics 
and primary care . . . practices[,] [(3)] [e]nhance the services provided at 
methadone clinics and the . . . medical care at practices providing buprenorphine[,] 
[and (4)] [a]ssure financial stability.”175  
In devising its Hub and Spoke model, Vermont, known nationally as a health 
care innovator,176 capitalized on its existing MAT infrastructure and its robust 
statewide health care delivery reform initiative, the Vermont Blueprint for Health 
(Blueprint).177 Enacted in 2008, the Blueprint transformed the primary care system 
for Vermont Medicaid beneficiaries by creating an intricate network of PCMHs 
and community health teams (CHTs) to improve population health, “enhance[] 
the quality of care and patient experience,” and reduce health care costs.178 
Consequently, the Hub and Spoke model was largely embedded into the provider 
relationships, primary care infrastructure, and payment reforms facilitated through 
implementation of the Blueprint.179  
Under the Hub and Spoke, patients receiving MAT have an “established 
medical home, [either an OTP or buprenorphine prescribing practice], a single 
MAT prescriber, a pharmacy home, access to existing Blueprint [CHTs], and 
access to Hub or Spoke nurses and clinicians.”180 Depending on the complexity and 
severity of the patient’s condition, patients are initially assigned to either a Hub or a 
Spoke, which is responsible for assessing the patient and devising an “integrated 
plan of care.”181 
 
 
                                                                                                                                                                           
http://blueprintforhealth.vermont.gov/sites/blueprint/files/BlueprintPDF/AnnualReports/VTBlueprintforHealthAnnual
Report2013.pdf [https://perma.cc/Q2VP-T2VB]; see also supra notes 169–173 and accompanying text.  
175 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 13; see also Casper & Folland, supra note 50, at 10 (footnote omitted).  
176 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 7; Simpatico, supra note 164, at 10 (“Vermont is one of the most forward-thinking states in the 
nation with a history of taking groundbreaking approaches to complex health and social issues.”).  
177 Moses & Klebonis, supra note 34, at 5. See VT. STAT. ANN. tit. 18 §§ 702–707, 709 (West 
2017), for discussion of Blueprint for Health initiatives.  
178 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 17 (citing DEP’T OF VT. HEALTH ACCESS, supra note 174, at 5); see also DEP’T OF VT. 
HEALTH ACCESS, supra note 169, at 2, 4–5; 46–47 (explaining Blueprint for Health initiatives). 
Because patients with complex health care needs often do not receive an adequate level of primary care 
services, CHTs are designed to “extend the capacity of primary care practices [by] assess[ing] patients’ 
needs, coordinat[ing] community-based support services, and provid[ing] multidisciplinary care.” DEP’T 
OF VT. HEALTH ACCESS, supra note 169, at 46; see also ASS’N OF STATE & TERRITORIAL HEALTH 
OFFICIALS & DEBEAUMONT FOUND., supra note 48, at 9. CHTs are “multi-disciplinary, community-
based care coordination and support teams,” ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & 
DEBEAUMONT FOUND., supra note 48, at 9, “comprised of nurse coordinators, clinician case managers, 
social workers[,] and other professionals.” DEP’T OF VT. HEALTH ACCESS, supra note 169, at 46.  
179 Casper & Folland, supra note 50, at 10–11; DEP’T OF VT. HEALTH ACCESS, supra note 169, at 
46–47, 54–57.  
180 DEP’T OF VT. HEALTH ACCESS, supra note 169, at 47.  
181 Casper & Folland, supra note 50, at 11. 
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i.  Hubs 
 
Patients with complex addictions and comorbid health conditions are assigned to Hubs, 
regional OTPs equipped to provide methadone, buprenorphine, “support for ongoing care 
and prevention and treatment of relapse,” and other services supporting the substance use 
disorder treatment plan.182 In addition to providing treatment, Hubs must be capable of 
either directly providing or referring patients to a variety of other services, including social 
welfare, housing, and employment services.183 Finally, Hubs are responsible for supporting 
Spokes through the provision of “induction and stabilization services for initiation of 
buprenorphine, reassessment and treatment recommendations if a patient  
relapses[,] . . . [and other] “recovery and rehabilitation services.”184  
 
ii.  Spokes 
 
In contrast to Hubs, Spokes provide buprenorphine in an outpatient setting and 
are designed to treat patients with less acute opioid dependence.185 A Spoke 
consists of a buprenorphine prescribing physician and “collaborating health and 
addictions professionals who monitor adherence to treatment, coordinate access to 
recovery supports and community services, and provide counseling, contingency 
management, care coordination[,] and case management services.”186 Spoke 
practice settings are most commonly “primary care, ob-gyn, psychiatry, and 
practices specializing in the management of chronic pain.”187 Blueprint initiatives 
require Spokes to have one full-time nurse and one full-time licensed clinician case 
manager for every 100 MAT patients.188  
Ideally, by integrating and coordinating delivery of care in Hubs and Spokes, 
“sufficiently stabilized” patients can transition from high intensity, high cost Hubs 
                                                                                                                                                                           
182 Id. at 11–12; see also DEP’T OF VT. HEALTH ACCESS, supra note 169, at 47.  
183 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 19 (footnote omitted); Casper & Folland, supra note 50, at 12. 
184 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 19. Consultation services may include “psychiatry, addictions medicine, expertise in manag[ing] 
co-occurring mental health conditions, and recovery supports.” Casper & Folland, supra note 50, at 12.  
185 Casper & Folland, supra note 50, at 11, 13; DEP’T OF VT. HEALTH ACCESS, supra note 169, at 
47–48. Although a Spoke must have a credentialed physician, the following health care providers can 
serve as Spokes: “Blueprint Advanced Practice Medical Homes[,] [o]utpatient SUD treatment 
providers[,] [p]rimary care providers[,] Federally Qualified Health Centers[, and] [i]ndependent 
psychiatrists.” CASPER & FOLLAND, supra note 50, at 13. 
186 DEP’T OF VT. HEALTH ACCESS, supra note 169, at 47. 
187 ANN VANDONSEL, VT. AGENCY OF HUMAN SERVS. DEP’T OF HEALTH, THE EFFECTIVENESS OF 
VERMONT’S SYSTEM OF OPIOID ADDICTION TREATMENT 6 (Jan. 15, 2015) (reporting to the Vermont 
Legislature), http://legislature.vermont.gov/assets/Legislative-Reports/Opioid-system-effectiveness-1.14.15.pdf 
[https://perma.cc/E85W-QN83]. 
188 Casper & Folland, supra note 50, at 13. The Blueprint contracts with or hires Spoke staff, who 
function as part of the local CHT and then work directly in Spoke physician practices. Id. Because most 
Spokes prescribe to less than 100 patients, Spoke staff are often shared across multiple practices. Id.  
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to lower cost “office-based” Spokes.189 Likewise, if a patient’s condition worsens, 
the patient may be escalated from a Spoke to a Hub to ensure the patient continues 
receiving adequate treatment.190  
 
D.  The Beneficial Impact of the Hub and Spoke Model 
 
Although Vermont is currently conducting a detailed evaluation of the impact 
of the Hub and Spoke model on “health care expenditures and utilization, clinical 
health outcomes, incarceration, and employment,” 191 the Hub and Spoke has 
already produced several beneficial results.192 The Hub and Spoke model has 
improved treatment capacity and access to care. Today, Vermont has five hubs with 
eight sites across the state, 193 which has tripled the number of patients receiving 
care in OTPs.194 Though Spokes have seen less dramatic improvements in 
treatment capacity, since 2013, the total number of buprenorphine prescribing 
physicians has grown approximately 64%, and the number of unique Medicaid 
patients seen monthly has increased 38%.195 The new delivery system also 
moderately increased the number of physicians actively treating ten or more 
Medicaid patients.196 Overall, a growing number of Medicaid beneficiaries rely on 
the Hub and Spoke for MAT,197 resulting in a 146% increase in the number of 
opioid dependent beneficiaries receiving treatment.198  
In addition to improving treatment capacity, the Hub and Spoke model has 
facilitated the provision of more individualized and coordinated care for opioid 
dependent beneficiaries. Initially, to improve delivery of care and aid entities in 
implementing delivery system changes, Vermont’s Medicaid program and the 
Vermont Department of Health Division of Alcohol and Drug Abuse Programs, 
devised standardized procedures and guidelines for the provision of MAT.199 The 
Hub and Spoke model has also given physicians greater flexibility in making 
treatment decisions. For instance, unlike traditional federal OTPs, which provide 
                                                                                                                                                                           
189 Id. at 18.  
190 Id.  
191 DEP’T OF VT. HEALTH ACCESS, VERMONT BLUEPRINT FOR HEALTH 2016 ANNUAL 
REPORT 53 (Dec. 29, 2016), 
http://blueprintforhealth.vermont.gov/sites/blueprint/files/BlueprintPDF/AnnualReports/Blueprint201
6AnnualReport12.29.16.pdf [https://perma.cc/Z42Q-DG8A]. 
192 See infra Section III.0. 
193 Casper & Folland, supra note 50, at 21.  
194 DEP’T OF VT. HEALTH ACCESS, supra note 191, at 50 (“The number of Vermonters in Hub 
programs . . . [went from] less than 1000 in 2013 to over 3,116 in October 2016.”).  
195 DEP’T OF VT. HEALTH ACCESS, supra note 191, at 48. 
196 Id. at 48–49; see Harry Chen, Status of Opioid Treatment Efforts, VT. DEP’T OF HEALTH 17 (Oct. 25, 2016), 
http://www.leg.state.vt.us/jfo/healthcare/Health%20Reform%20Oversight%20Committee/2016_10_25/Status%20of%2
0Opioid%20Treatment%20Efforts%20-%20Chen.pdf [https://perma.cc/2AZ7-3DZC] (noting that as of October 2016, 
“45% of [S]poke prescribers prescribe[d] to more than 10 patients).  
197 Casper & Folland, supra note 50, at 22.  
198 Chen, supra note 196, at 16. The increased number of beneficiaries receiving treatment was 
largely due to increased caseloads in Hubs. VANDONSEL, supra note 187, at 9.  
199 VANDONSEL, supra note 187, at 19.  
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methadone almost exclusively, Hub physicians have the autonomy to determine 
whether a patient should initially be treated with buprenorphine or methadone.200 
The collaboration between Hubs and Spokes has also allowed approximately one-
third of patients stabilized with buprenorphine in Hubs to continue treatment 
while transitioning to less intensive, less costly care in Spokes.201 Throughout the 
course of the delivery system changes, 90-day treatment retention rates, which are 
crucial to treatment efficacy and the patient’s long term functioning, have remained 
higher than the national average and continue to show an increasing trend.202  
From a cost perspective, despite substantial investments in delivery system 
infrastructure and the imposition of higher medication costs through expanded use 
of buprenorphine, the Hub and Spoke model is expected to reduce overall health 
care expenditures.203 A study conducted prior to complete implementation of the 
Hub and Spoke found that Medicaid beneficiaries receiving MAT with methadone 
or buprenorphine had lower overall annual health care expenditures than those 
receiving non-medication interventions.204 This cost difference was partially 
explained by fewer inpatient admissions and outpatient hospital emergency 
department visits among MAT beneficiaries.205 When compared to the average 
cost of a privately insured person with opioid use disorder, the average cost per 
person of a beneficiary participating in the Hub and Spoke system is approximately 
$46,954 less.206 Ultimately, as of 2014, the Department of Vermont Health Access 
projected that “[d]ecreases in unnecessary and even higher-cost health care 
                                                                                                                                                                           
200 Casper & Folland, supra note 50, at 17 & n.11; see supra note 136–138 and accompanying text 
(highlighting the inefficiency of the limited prescription of buprenorphine in OTPs despite the fact 
OTPs are subject to less prescribing restrictions than physicians).  
201 Casper & Folland, supra note 50, at 18. 
202 VANDONSEL, supra note 187, at 15–16; VT. DEP’T OF HEALTH DIV. OF ALCOHOL & DRUG 
ABUSE PROGRAMS, VT. AGENCY OF HUMAN SERVS., ANNUAL REPORT ON VERMONT’S 
SUBSTANCE ABUSE SYSTEM OF CARE 23–24 (Jan. 13, 2016) (reporting to Vermont Legislature), 
http://legislature.vermont.gov/assets/Legislative-Reports/SA-annual-report-for-submission1.13.16.pdf 
[https://perma.cc/L2NS-PUEC]. Because of the enhanced intensity of care in Hubs, average retention 
rates in Hubs are 82.8%, compared to 69.3% in Spokes. VANDONSEL, supra note 187, at 15–16. As of 
2014, retention rates had increased 4% since 2012. VT. DEP’T OF HEALTH DIV. OF ALCOHOL & 
DRUG ABUSE PROGRAMS, supra, at 23–24.  
203 Casper & Folland, supra note 50, at 16, 27.  
204 Mohlman et al., supra note 112, at 12–13. Average annual total medical expenditures among 
beneficiaries receiving MAT were $412 lower per beneficiary than expenditures in the non-MAT 
group. Id. at 12. When opioid addiction treatment costs were excluded, total expenditures were $2,409 
lower for beneficiaries receiving MAT. Id. Beneficiaries in the MAT group also had “higher rates of 
pre- and perinatal care, [Hepatitis C virus] positivity, and more severe health status.” Id.; see also supra 
notes 151–52 (providing further support for notion that medication costs may be offset by a reduction in 
other health care costs).  
205 Mohlman et al., supra note 112, at 12.  
206 Chen, supra note 196, at 22 (citing FAIR HEALTH, THE IMPACT OF THE OPIOID CRISIS ON 
THE HEALTHCARE SYSTEM 6 (Sept. 2016), https://www.fairhealth.org/publications/whitepapers 
(follow “Sep 2016: The Impact of the Opioid Crisis on the Healthcare System” hyperlink) 
[https://perma.cc/C7KQ-74NG]).  
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expenditures . . . [and] societal impacts and savings . . . in areas such as corrections, 
employment, . . . children in custody,” and increases in productivity, would result in 
savings of $6.7 million.207  
 
E.  Limitations of the Hub and Spoke Model 
 
Though the Hub and Spoke model appears to be a promising model for 
delivering MAT, Vermont has also experienced several challenges in its 
implementation and maintenance of the Hub and Spoke. Despite augmented 
treatment capacity and access under the Hub and Spoke model, the system remains 
inadequate to meet treatment demand.208 This is evidenced by the fact that the 
increased caseload of patients receiving treatment has only marginally affected the 
widespread availability of heroin and the growing prevalence of heroin addiction.209 
Furthermore, regardless of Vermont’s enhanced capacity to treat patients, many 
persons in need of treatment never seek care.210 People most commonly cited 
affordability, lack of a desire to stop using opioids, lack of information regarding 
where to seek treatment, health insurance coverage issues, and transportation as 
reasons for not getting treatment.211 Consequently, one’s decision to forego 
treatment may be unrelated to a lack of access.  
Although the transferability of patients in the current system marked a 
significant shift from the former system,212 several limitations have plagued 
development of the ideal, synergistic relationship between Hubs and Spokes. Even 
with the baseline network of providers formed through the Blueprint initiative, 
establishing the processes, protocols, and relationships necessary to freely and 
efficiently transfer patients between Hubs and Spokes has been a substantial 
challenge.213 While the Hub and Spoke dramatically increased patient caseload in 
Hubs, there was no parallel shift in the number of physicians prescribing 
buprenorphine214 or the number of physicians actively treating more than ten 
patients.215 Therefore, the shortage of medical providers in Spokes has restricted 
                                                                                                                                                                           
207 Casper & Folland, supra note 50, at 27 (footnotes omitted).  
208 DEP’T OF VT. HEALTH ACCESS, supra note 191, at 47–48, 50–51; see also id. at 51 (noting that 
improvements in access to care largely varied by region); Casper & Folland, supra note 50, at 23; id. 
(“Continued waitlists . . . in the system show that the Hub and Spoke system is still facing unmet 
need.”). 
209 VT. DEP’T OF HEALTH DIV. OF ALCOHOL & DRUG ABUSE PROGRAMS, supra note 202, at 7, 
14. 
210 Id. at 19. 
211 Id. 
212 Casper & Folland, supra note 50, at 18. 
213 Id. at 18–19. 
214 VANDONSEL, supra note 187, at 9, 12. 
215 See DEP’T OF VT. HEALTH ACCESS, supra note 191, at 48–49; Chen, supra note 196, at 17 
(indicating that most “spoke prescribers prescrib[ing] to more than [ten] patients” predominantly 
prescribe to “their own primary care patients with opioid use disorders”).  
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care coordination, causing patients to remain in Hubs even when treatment in a 
Spoke is more appropriate.216 
Vermont has actively attempted to encourage health care providers to offer 
MAT through trainings and other support,217 but the following barriers persistently 
limit access and capacity to treat and coordinate care: “[(1)] patient complexity[,] 
[(2)] provider time[,] [(3)] lack of access to specialty care[,] [(4)] [physicians’] 
concern that [their] practice[s] will be flooded with too many addiction[] patients[, 
and] [(5)] skepticism about the efficacy of MAT.”218 In addition to workforce 
development challenges, federal regulations prohibiting sharing of substance use 
treatment information in the absence of the patient’s consent have created another 
formidable obstacle to “effective integration of care and sharing of vital 
information.”219 Issues with information sharing are partially alleviated if a patient 
signs a standard release form containing the requisite elements,220 but the release 
form still limits substance abuse providers’ ability to access crucial information 
regarding the treatment or medications a patient received in a Hub.221 
Thus, as Vermont continues to invest in its Hub and Spoke model and address 
the issues that have emerged thus far in implementation, it will be crucial to 
analyze whether the innovative health home model approach to delivering MAT 
improves health outcomes. 
 
IV.  THE EFFICACY OF VERMONT’S MEDICATION ASSISTED TREATMENT 
DELIVERY SYSTEM 
 
Because of the unique demographic characteristics of Vermont’s general and 
Medicaid populations, and its status as an innovative health care state, states 
considering whether to adopt a Medicaid health home parallel to Vermont’s for the 
provision of MAT have reason to be skeptical. To address the opioid drug crisis, 
improve patient care, and reduce overall health expenditures, Vermont “combined a 
high cost structure with high cost medication.”222 In fact, from 2012 to 2016, 
Vermont’s Medicaid spending on opioid treatment has nearly quadrupled;223 and, 
                                                                                                                                                                           
216 VT. DEP’T OF HEALTH DIV. OF ALCOHOL & DRUG ABUSE PROGRAMS, supra note 202, at  
19–20; Chen, supra note 196, at 19.  
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amidst a large budget deficit, which some attribute to “[m]ushrooming Medicaid 
[c]osts,”224 pressure on the Hub and Spoke model’s success builds.225 
But, in combination with the substantial increase in Medicaid spending, several 
of Vermont’s distinguishing features may add further discomfort to states seeking 
an effective solution to the impending opioid drug crisis. Not only does Vermont 
have one of the highest rates of treatment capacity for opioid dependence,226 it is 
also one of the smallest and least diverse states.227 Compared to other states, 
Vermont spends more generously on its Medicaid population and therefore at 
baseline may be more willing to consider certain treatment options than other 
states. For instance, Vermont spends more per Medicaid enrollee than most 
states228 despite having a Federal Medical Assistance Percentage (FMAP) of 
53.47%, which indicates that Vermont has a higher per capita income than most 
states and is responsible for a greater portion of Medicaid costs.229 In addition to 
demographic distinctions, Vermont implemented its Hub and Spoke model within 
the foundation of the Blueprint initiative,230 which essentially made medical homes 
a central component of the state’s Medicaid program. Not only did the Blueprint 
initiative provide a baseline network of providers across multiple agencies, it also 
facilitated the adoption of payment mechanisms rewarding the provision of quality, 
value based care rather than the traditional volume-based, fee-for-service form of 
reimbursement found in most states’ Medicaid programs.231 
Overall, Vermont’s progressive approach should not discourage other states 
from considering innovative approaches, such as the health home model, to 
improve delivery of MAT to opioid dependent Medicaid beneficiaries. But, as 
states analyze the feasibility of implementing such a system, it is apparent that the 
challenges and resources necessary to create the proper infrastructure for the health 
home model could be more substantial in other states. The health home model 
dramatically alters traditional relationships among health care providers from both 
a payment and treatment perspective. Without a baseline initiative, such as 
                                                                                                                                                                           
224 Nancy Remsen, Mushrooming Medicaid Costs Create a State Budget Crisis, VT.’S INDEP. 
VOICE: SEVEN DAYS (Jan. 13, 2016), http://www.sevendaysvt.com/vermont/mushrooming-medicaid-
costs-create-a-state-budget-crisis/Content?oid=3111005 [https://perma.cc/2DYZ-MXP4]. 
225 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 35. 
226 VanDonsel et al., supra note 168, at 6 (citing Jones et al., supra note 87, at e59–60). 
227 ASS’N OF STATE & TERRITORIAL HEALTH OFFICIALS & DEBEAUMONT FOUND., supra note 
48, at 7. 
228 See State Health Facts: Medicaid Spending Per Full-Benefit Enrollee, KAISER FAMILY 
FOUND., https://www.kff.org/state-category/medicaid-chip/medicaid-spending-per-enrollee/ 
[https://perma.cc/E4J5-G2YC] (follow “Medicaid Spending Per Full-Benefit Employee” 
hyperlink) (last visited Nov. 18, 2017) (estimating spending per full-benefit employee as of 
fiscal year 2014). 
229 State Health Facts: Federal Medical Assistance Percentage (FMAP) for Medicaid and 
Multiplier, KAISER FAMILY FOUND., https://www.kff.org/state-category/medicaid-chip/medicaid-
spending/ [https://perma.cc/B7DX-T65B] (follow “Federal Medical Assistance Percentage (FMAP) for 
Medicaid and Multiplier” hyperlink (last visited Nov. 18, 2017). 
230 See supra notes 176–179 and accompanying text. 
231 Casper & Folland, supra note 50, at 19; DEP’T OF VT. HEALTH ACCESS, supra note 191, at 11. 
2017–2018                     Implementing Medicaid Health Homes to Provide 
           Medication Assisted Treatment to Opioid Dependent 
                                                   Medicaid Beneficiaries 
 
 
 
 
143 
Blueprint, which transformed the organization of health care delivery in Vermont’s 
Medicaid system, other states are at a significant disadvantage to attain the cost 
savings that may result from an improvement in health outcomes. Nonetheless, by 
eliminating the division between OTPs, buprenorphine prescribing physicians, and 
the overall health care system, and providing integrated care that addresses a 
patient’s opioid dependence and other comorbid conditions, Vermont’s Hub and 
Spoke model, and the health home model generally, offers states important insights 
into how MAT delivery can most effectively be modified to improve health 
outcomes. 
 
CONCLUSION 
 
Though the ACA was not originally designed with the opioid epidemic in 
view, its provisions, including Medicaid expansion, state health insurance 
exchanges, and the inclusion of addiction treatment as an essential health benefit, 
have provided insurance coverage to millions of Americans suffering from 
substance use disorders, including approximately one third with opioid use 
disorders.232 Medicaid expansion alone is estimated to have provided drug 
treatment to approximately 1.3 million Americans.233 Repeal of the ACA would 
eliminate such coverage of substance abuse treatment and “turn the clock back to a 
time when most Americans were subject to restrictive and inequitable limits on 
coverage” for MAT and other treatment services.234 Consequently, “repeal and 
replace effort[s] [come] . . . at a critical time in the fight against opioid 
addiction.”235 Leaving Medicaid coverage of drug treatment and mental health 
services to state discretion means not only that fewer people would receive 
necessary treatment, but also that coverage of substance abuse treatment would be 
increasingly subject to state budgetary pressures.236  
The opioid drug crisis “cuts across the lines of political polarization” and affects 
“nearly every community in this country.”237 Whether it is through the ACA or a 
different health plan, Medicaid coverage of opioid dependence prevention and 
treatment is crucial. As states brace for looming health policy changes, 
implementing a health home model for opioid dependent Medicaid beneficiaries 
remains a viable option for reforming the delivery of MAT. Undoubtedly, forming 
the infrastructure necessary to operate a health home is a significant undertaking. 
But, by building upon components of the existing treatment system and providing 
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more coordinated, effective care, it is possible that, in the long run, the health 
home model could help states reduce opioid-related morbidity and mortality and 
achieve overall cost savings.  
 
